Cover Page  for Protocol  
Sponsor name:  [CONTACT_3454] A/S  
NCT number  [STUDY_ID_REMOVED] 
Sponsor t rial ID:  EX9536-4665 
Official title of study:  Effect of semaglutide s.c. 2.4 mg once weekly on function and
symptoms in subjects with obesity-related heart failure with
preserved ejection fraction
Document date *: 21 June 2023 
*Document date refers to the date on which the document was most recently updated.
Note: The date in the header from Page [ADDRESS_1108913] of contents
Protocol ...............................................................................................................................................
Attachment I and II ............................................................................................................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide s.c. 2.4 mg once weekly
Study ID: EX9536-4665
Clinical Study Report
Appendix 9.1.121 June 2023
1.0
Final
9.1.1 Protocol and protocol amendments
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  1 of 88 
 
Protocol  
Including Amendment 1 , dated 05 January 2021  
Including Amendment 2, dated 07 January 2021  
Including Amendment 3, dated 2 1, January 2021  
Including Amendment 4, dated 12 February 2021  
Including Amendment 5, dated 09 September 2022  
 
 
STEP -HFpEF  
Protocol title: Effect of semaglutide 2.4 mg once weekly on function and symptoms in 
subjects with obesity -related heart failure  with  preserved ejection fraction  
Substance: semaglutide  
Universal Trial Number: U1111 -[ADDRESS_1108914] Number: 2019 -004452 -11 
Trial phase:  3a 
In the following, Novo Nordisk A/S and its affiliates will be stated as “Novo Nordisk”.  
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.  
  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  [ADDRESS_1108915] be restricted to relevant 
parties.
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  2 of 88 
 
Protocol amendment summary of changes table  
DOCUMENT HISTORY  
 
Document version  Date  Applicable in country( -ies) and/or site(s)  
Protocol version 6.0 (including 
amendment 5)  09 Sep 2022  All 
Protocol version 5.0 (including 
amendment 4)  12 Feb 2021  [LOCATION_013]  
Protocol version 4.0 (including 
amendment 3)  21 Jan 2021  All 
Protocol version 3.0 (including 
amendment 2)  07 Jan 2021  [LOCATION_013]  
Protocol version 2.0 (including 
amendment 1)  05 Jan 2021  [LOCATION_008]  
Protocol version 1.0  28 Sep 2020  All 
 
Protocol version 6.0 (09 September 2022) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of  
Directive 2001/20/EC of the European Parliament and the Council of the European Union .1 
 
Overall rationale for preparing protocol, version 6.0: 
The overall rationale for the change s implemented in the amended protocol is an increasing interest 
in reporting results in a manner that reflects the clinical relevance across di fferent domains 
including patient -reported outcomes combined with objective measures  and events . 
 
Section # and name  [CONTACT_18054] 1.1 Synopsis  Win ratio composite endpoint added to 
confirmatory secondary endpoints  See overall rationale  
Section 3.1 Primary, secondary and 
exploratory objectives and estimand  Secondary objectives changes to address 
added confirmatory secondary endpoint  See overall rationale  
Section [IP_ADDRESS] Confirmatory 
secondary endpoints  Win ratio composite endpoint added to 
confirmatory secondary endpoints  See overall rationale  
Section [IP_ADDRESS] Supportive 
secondary endpoints  Endpoints related to weight loss, KCCQ -CSS 
and 6MWD added to supportive secondary 
endpoints  Alignment with SAP  
Section 3.2.[ADDRESS_1108916] changes to the 
testing hierarchy  See overall rationale  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 2 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  3 of 88 
 
Section [IP_ADDRESS] Statistical analyses 
Confirmatory secondary endpoints  Description of statistical analyses updated to 
reflect inclusion of Win Ratio composite 
endpoint in confirmatory secondary endpoints  See overall rationale  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 3 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  4 of 88 
 
Table of Contents   
 Page  
Protocol amendment summary of changes table  ................................ ................................ ...........................  2 
Table of Contents ................................ ................................ ................................ ................................ ..............  4 
1 Protocol summary  ................................ ................................ ................................ ................................ ..... 7 
1.1 Synopsis  ................................ ................................ ................................ ................................ ...........  7 
1.2 Flowchart  ................................ ................................ ................................ ................................ ....... 10 
2 Introduction  ................................ ................................ ................................ ................................ .............  13 
2.1 Trial rationale  ................................ ................................ ................................ ................................ . 13 
2.2 Background  ................................ ................................ ................................ ................................ .... 14 
2.3 Benefit -risk assessment  ................................ ................................ ................................ ..................  14 
2.3.1  Risk assessment  ................................ ................................ ................................ ...............  15 
2.3.2  Benefit assessment  ................................ ................................ ................................ ...........  16 
2.3.3 Overall benefit -risk conclusion  ................................ ................................ .......................  16 
3 Objectives and endpoints  ................................ ................................ ................................ ........................  17 
3.1 Primary, secondary and exploratory objectives and estimand  ................................ .......................  17 
3.2 Primary, secondary and exploratory endpoint(s)  ................................ ................................ ...........  18 
3.2.1  Multiple primary endpoints  ................................ ................................ .............................  18 
3.2.2  Secondary endpoints  ................................ ................................ ................................ ........  18 
[IP_ADDRESS]  Confirmatory secondary endpoints  ................................ ................................ . 18 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... 19 
3.2.3  Exploratory endpoint(s)  ................................ ................................ ................................ ... 20 
4 Trial design  ................................ ................................ ................................ ................................ ..............  21 
4.1 Overall design  ................................ ................................ ................................ ................................  21 
4.2 Scientific rationale for trial design  ................................ ................................ ................................ . 21 
4.3 Justification for dose  ................................ ................................ ................................ ......................  22 
4.4 End of trial definition  ................................ ................................ ................................ .....................  22 
5 Trial population  ................................ ................................ ................................ ................................ ....... 23 
5.1 Inclusion criteria  ................................ ................................ ................................ ............................  23 
5.2 Exclusion criteria  ................................ ................................ ................................ ...........................  24 
5.3 Lifestyle considerations  ................................ ................................ ................................ .................  25 
5.4 Screen failures  ................................ ................................ ................................ ................................  25 
6 Treatments  ................................ ................................ ................................ ................................ ...............  26 
6.1 Treatments administered  ................................ ................................ ................................ ................  26 
6.1.1  Medical devices  ................................ ................................ ................................ ...............  28 
6.2 Preparation/handling/storage/accountability  ................................ ................................ ..................  [ADDRESS_1108917]’s home  ................................ ................................ .... 29 
6.3 Measures to minimise bias: Randomisation and blinding  ................................ .............................  [ADDRESS_1108918]  discontinuation/withdrawal  ................................ ..... [ADDRESS_1108919] discontinuation/withdrawal from the trial  ................................ ................................ .........  [ADDRESS_1108920] to follow -up ................................ ................................ ................................ ...........................  34 
8 Trial assessments and procedures  ................................ ................................ ................................ .........  35 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 4 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  5 of 88 
 
8.1 Efficacy assessments  ................................ ................................ ................................ ......................  35 
8.1.1  Body measurements  ................................ ................................ ................................ .........  35 
8.1.2  Clinical outcome assessments  ................................ ................................ .........................  35 
8.1.3  Echocardiography  ................................ ................................ ................................ ............  37 
8.1.4  Clinical laboratory assessments  ................................ ................................ .......................  37 
8.2 Safety assessments  ................................ ................................ ................................ .........................  37 
8.2.1  Physical examinations  ................................ ................................ ................................ ..... 37 
8.2.2  Vital signs  ................................ ................................ ................................ ........................  37 
8.2.3  Electrocardiograms  ................................ ................................ ................................ ..........  38 
8.2.4  [LOCATION_001] Heart Association (NYHA) classification  ................................ .....................  38 
8.2.5  Clinical safety laboratory assessments  ................................ ................................ ............  38 
8.3 Adverse events and serious adverse events  ................................ ................................ ....................  38 
8.3.1  Time period and frequency for collecting AE and SAE information  ..............................  40 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ................  40 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ...........................  40 
8.3.4  Regulatory reporting requirements for SAEs  ................................ ................................ .. 40 
8.3.5  Pregnancy  ................................ ................................ ................................ ........................  41 
8.3.6  Cardiovascular and death e vents  ................................ ................................ .....................  41 
8.3.7  Technical complaints  ................................ ................................ ................................ ....... 41 
8.4 Treatment of overdose  ................................ ................................ ................................ ...................  41 
8.5 Pharmacokinetics  ................................ ................................ ................................ ...........................  41 
8.6 Pharmacodynamics  ................................ ................................ ................................ ........................  42 
8.7 Genetics  ................................ ................................ ................................ ................................ .........  42 
8.8 Biomarkers  ................................ ................................ ................................ ................................ ..... 42 
8.9 Immunogeni city assessments  ................................ ................................ ................................ .........  43 
8.10  Health economics  ................................ ................................ ................................ ...........................  43 
9 Statistical considerations  ................................ ................................ ................................ ........................  44 
9.1 Statistical hypotheses  ................................ ................................ ................................ .....................  44 
9.2 Sample size determination  ................................ ................................ ................................ .............  45 
9.3 Populations for analyses  ................................ ................................ ................................ ................  47 
9.4 Statistical analyses  ................................ ................................ ................................ .........................  47 
9.4.1  General considerations  ................................ ................................ ................................ .... 47 
9.4.2  Primary endpoints  ................................ ................................ ................................ ............  47 
9.4.3 Secondary endpoint(s)  ................................ ................................ ................................ ..... 48 
[IP_ADDRESS]  Confirmatory secondary endpoint  ................................ ................................ ... 48 
[IP_ADDRESS]  Supportive secondary endpoints  ................................ ................................ ..... 49 
9.4.4  Exploratory endpoints  ................................ ................................ ................................ ..... 49 
[IP_ADDRESS]  Pharmacokinetic and/or pharmacodynamic modelling  ................................ ... 49 
9.5 Interim analyses  ................................ ................................ ................................ .............................  49 
9.6 Data monitoring committee  ................................ ................................ ................................ ...........  49 
9.7 Reporting of the main part of the trial ................................ ................................ ............................  49 
10 Supporting documentation and operational considerations  ................................ ...............................  50 
10.1  Appendix 1: Regulatory, ethical, and trial oversight considerations  ................................ .............  50 
10.1.1  Regulatory and ethical considerations  ................................ ................................ .............  50 
10.1.2  Financial disclosure  ................................ ................................ ................................ .........  50 
10.1.3  Informed consent process  ................................ ................................ ................................  50 
10.1.4  Information to subjects during trial  ................................ ................................ .................  51 
10.1.5  Data protection  ................................ ................................ ................................ ................  51 
10.1.6  Committees structure  ................................ ................................ ................................ ....... 52 
[IP_ADDRESS]  Novo Nordisk safety committee ................................ ................................ ...... 52 
[IP_ADDRESS]  Event adjudication committee  ................................ ................................ .........  52 
[IP_ADDRESS]  Steering committee  ................................ ................................ .........................  52 
10.1.7  Dissemination of clinical trial data  ................................ ................................ ..................  52 
10.1.8  Data quality assurance  ................................ ................................ ................................ ..... 52 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 5 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September  2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
Status:  Final  
Page:  6 of 88 
[IP_ADDRESS]  Case report forms  ................................ ................................ ............................  52
[IP_ADDRESS]  Monitoring  ................................ ................................ ................................ ...... 53
[IP_ADDRESS]  Protocol compliance  ................................ ................................ ........................  54
10.1.9  Source documents  ................................ ................................ ................................ ............  54
10.1.10 Retention of clinical trial documentation  ................................ ................................ ........  54
10.1.11  Trial and site closure  ................................ ................................ ................................ ....... 55
10.1.12  Responsibilities ................................ ................................ ................................ ................  55
10.1.13  Indemnity statement  ................................ ................................ ................................ ........  56
10.1.14  Publication policy  ................................ ................................ ................................ ............  56
[IP_ADDRESS]  Communication of results  ................................ ................................ ...............  56
[IP_ADDRESS]  Authorship  ................................ ................................ ................................ ....... 57
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s) ................................ .................  57
[IP_ADDRESS]  Investigator access to data and review of results  ................................ ............  57
10.2  Appendix 2: Clinical laboratory  tests ................................ ................................ ............................  58
10.3  Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, follow -
up, and reporting  ................................ ................................ ................................ ............................  59
10.3.1 Definition of AE  ................................ ................................ ................................ ..............  59
10.3.2 Definition of an SAE  ................................ ................................ ................................ ....... 59
10.3.3 Description of events for adjudication and AEs requiring additional data collection  ..... 61
10.3.4 Recording and follow -up of AE and/or SAE  ................................ ................................ ... 62
10.3.5 Reporting  of SAEs  ................................ ................................ ................................ ...........  63
10.4  Appendix 4: Contraceptive guidance and collection of pregnancy information  ............................  65
10.5  Appendix 5: Technical complaints: Definition and procedures for recording, evaluation, 
follow -up and reporting  ................................ ................................ ................................ .................  68
10.5.1  Definition of technical complaint  ................................ ................................ ....................  68
10.5.2  Recording and follow -up of technical complaints  ................................ ...........................  68
10.6 Appendix 6: Retention of human biosamples and genetics  ................................ ...........................  70
10.7 Appendix 7: Country -specific requirements  ................................ ................................ ..................  71
10.8 Appendix 8: Mitigations to ensure patient s afety and data integrity during an emergency 
situation  ................................ ................................ ................................ ................................ ..........  73
10.9 Appendix 9: Abbreviations  ................................ ................................ ................................ ............  78
10.10  Appendix 10: Protocol amendment history  ................................ ................................ ...................  [ADDRESS_1108921] of key staff and relevant departments. 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 6 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  7 of 88 
 
1 Protocol summary  
1.1 Synopsis  
Rationale:  
Heart failure with preserved ejection fraction (HFpEF) in patients with obesity is associated  with 
decreased health -related quality of life, worse heart failure symptoms, greater systemic 
inflammation and lower exercise capacity compare d to HFpEF patients without obesity. A study of 
subjects with HFpEF and obesity has indicated that a weight loss of 3 -7 kg increases exercise 
tolerance and HF -specific health -related quality of life .  
Objectives and endpoints:  
Primary objective  
To investig ate the effects of semaglutide subcutaneous (s.c.) 2.[ADDRESS_1108922] of care, in subjects with 
obesity -related  HFpEF.  
Primary estimand  
The estimand will quantify the average change from baseline in Kansas City Cardiomyopathy 
Questionnaire (KCCQ) clinical summary score and average change from baseline in body weight of 
semaglutide s.c. 2.[ADDRESS_1108923] of care, after 
52 weeks, in all randomised subjects regardless of adherence to randomised treatment (“treatment 
policy” estimand).  
Multiple primary endpoints  
Endpoint title  Time frame  Unit  
Change in KCCQ clinical summary 
score  From baseline (we ek 0) to end of 
treatment (week 52) Score (no unit, range; 0 -100) 
Change in body weight  From baseline (week 0) to end of 
treatment ( week  52)  % 
Confirmatory secondary endpoints  
Endpoint title  Time frame  Unit  
Change in 6 -minute walking distance  From baseline (week 0) to end of 
treatment (week 52)  Metres  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 7 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  8 of 88 
 
Hierarchical composite of:  
Time to all -cause death,  
number of heart failure events requiring 
hospi[INVESTIGATOR_803275],  
time to first heart failure event 
requiring hospi[INVESTIGATOR_803276],  
difference at least [ADDRESS_1108924] 30 metres in six -
minute walking distance change from 
baseline to 52 weeks  
(assessed by [CONTACT_15604])  From baseline (week 0) to end of 
study (week 57)  Total wins for each treatment 
group  
Change in C -Reactive Protein  From baseline (week -2) to end of 
treatment (week 52)  Ratio to baseline (no unit)  
Overall design:  
This is a 52-week, randomised, placebo -controlled, double blind, multi -centre clinical trial 
comparing semaglutide s.c. 2.4 mg w ith placebo in subjects with obesity -related  HFpEF.   
Eligible subjects will be randomised in a 1:[ADDRESS_1108925] of care.  
Key inclusion criteria  
 Male or female, age above or equal to 18 years at the time of signing informed consent.  
 Body mass index (BMI) ≥ 30.0 kg/m2  
 [LOCATION_001] Heart Association ( NYHA ) Class II -IV 
 Left ventricular ejection fraction (LVEF) ≥ 45 % at screening  
Key exclusion criteria  
 A self -reported change in body weight > 5 kg (11 lbs) within 90 days before screening 
irrespective of medical records  
 Haemoglobin  A1c (HbA 1c) ≥ 6.5 % (48 mmol/mol) based on latest available value from medical 
records, no older than 3 months or if unavailable a local measurement at scree ning 
Number of subjects:  
[ADDRESS_1108926].  
Treatment groups and duration:  
The total trial duration for the individual subject will be approximately 59 weeks. The trial includes 
a screening period o f approximately 2 weeks. Eligible subjects will at visit 2 be randomised in a 1:1 
manner to receive either semaglutide 2.4 mg once  weekly or placebo once  weekly as add -on to 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 8 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108927] 16 weeks, the dose of semaglutide or placebo will be gradually 
escalated from 0.2 5 mg once  weekly until target dose. The treatment will continue until the ‘end of 
treatment’ visit followed by a 5 weeks follow -up period.  
The following trial products will be supplied by [CONTACT_3454] A/S:  
 Semaglutide D 0.5 mg/mL , solution  for injection,  DV3396  0.5mL  pen-injector  
 Semaglutide D 1.0 mg/mL , solution for injection,  DV3396  0.5 mL pen -injector  
 Semaglutide D 2.0 mg/mL , solution for injection,  DV3396  0.5 mL pen -injector  
 Semaglutide D 2.27 mg/mL , solution for injection,  DV3396  0.75 mL pen -injector  
 Semaglutide D 3.2 mg/mL , solution for injection,  DV3396 0.75 mL pen -injector   
 Semaglutide placebo Ia , solution for injection,  0.5mL pen -injector  
 Semaglutide placebo  Ib, solution for injection,  0.75 mL pen -injector  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 9 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  10 of 88 
 
1.2 Flowchart  
 Screening  Randomisation  Main tenance period  End of 
treatment  End of trial  
Visit /Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +7  
Informed consent and demographya (10.1.3 ) X            
Inclusion and exclusion criteria ( 5.1, 5.2) X X           
Physical examination ( 8.2.1 ) X X         X  
Medical history/Concomitant illness ( 8.2.1 ), Tobacco useb   X           
Childbearing potential ( 10.2, 10.4) X            
Concomitant medication ( 6.5)  Xc X X X X Xc X Xc X Xc X 
Body weight ( 8.1.1 ) X X X X X X X X X X X  
Height / BMI ( 8.1.1 ) X            
Waist circumference ( 8.1.1 )  X     X    X  
Patient Global Impression of Status (PGI -S) for KCCQ ( 8.1.2 ) X X     X  X  X  
Patient Global Impression of Change (PGI -C) for KCCQ ( 8.1.2 )  X     X  X  X  
Kansas City Cardiomyopathy Questionnaire (KCCQ) ( 8.1.2 ) X X     X  X  X  
European Quality of Life five Dimensions five Level (EQ -5D-5L) ( 8.1.2 )  X     X    X  
Patient Global Impression of Status (PGI -S) for 6MWT ( 8.1.2 ) X X     X    X  
Patient Global Impression of Change (PGI -C) for 6MWT ( 8.1.2 )  X     X    X  
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 10  of 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  11 of 88 
 
 Screening  Randomisation  Main tenance period  End of 
treatment  End of trial  
Visit /Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +[ADDRESS_1108928] (6MWT) ( 8.1.2 ) X X     X    X  
NYHA  classification  / Vital Signs  (8.2.2 , 8.2.4 )  X      X    X  
Electrocardiogram (ECG) ( 8.2.3 ) X          X  
Echocardiography ( 8.1.3 ) X Xd         Xd  
Laboratory assessments ( 10.2) X X     X    X  
Semaglutide plasma concentration  (10.2)       X    X  
Pregnancy test (only for women of childbearing potential)e (10.2) X X  X X  X X X X X X 
Healthy lifestyle counselling ( 5.3)  X X X X X X X X X X  
Adverse event and Events for adjudication ( 8.3, 10.3)   X X X X X X X X X X 
Medication error , Misuse and Abuse  (8.3, 10.3.3 )  X X X X X X X X X X  
Drug dispensing ( 6)  
X X X X X X X X X   
Training in trial product, pen -handling ( 6.1)  X X X X    X    
Hand Out Directions for Use  (6.1)  X           
Hand Out Dose Reminder Card   X X X X X       
Hand Out ID Card  X            
Drug Accountability  (6.2)  X X X X X X X X X X  
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 11  of 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  12 of 88 
 
 Screening  Randomisation  Main tenance period  End of 
treatment  End of trial  
Visit /Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +7  
IWRS session  X X X X X X X X X X X  
a) Demography consists of date of birth, sex, race and ethnicity (according to local regulation – [LOCATION_013]: for country -specific requirements, please see Appendix 7 (Section 10.7)). 
b) Tobacco use is defined as smoking at least one cigarette or equivalent daily . 
c) Dose to be collected for loop diuretics . 
d) Only relevant for subjects included in the echocardiographic sub -study . 
e) For women of childbearing potential only. In addition to the planned assessments, urine dipstick pregnancy test should be per formed at any time during the trial if a menstrual period is 
missed, or if pregnancy is suspected.  (according to local regulation  – [LOCATION_008] and [LOCATION_013]: for country -specific requirements, please see Appendix 7 (Section 10.7)). 
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 12  of 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108929] of body weight 
reduction obtained by [CONTACT_803296].  
Semaglutide  
Semaglutide is the next generation glucagon -like peptide -1 (GLP -1) analogue currently under 
development by [CONTACT_156044] (NN9536, including the 
phase 3a STEP programme). Semaglutide has been optimised resulting in a longer half -life of 
approximately 160 hours, making it suitable for once -weekly dosing.3  GLP -1 is a physiological 
regulator of appetite and GLP -1 receptors are present in several areas of the brain involved in 
appetite regul ation4. 
Clinical5-27 and non -clinical28 data indicate that the body weight (BW) reducing effect of 
semaglutide is mainly mediated by [CONTACT_803297].  2.[ADDRESS_1108930] a safe and well -tolerated profile (STEP programme), as seen with  previous trials.   
A comprehensive review of results from the non -clinical and clinical studies of semaglutide can be 
found in the current version of the investigator’s brochure (IB)29 or any updates hereof.  
In the following, unless otherwise stated, “semaglutide 2.4 mg” will refer to semaglutide s.c. 2.[ADDRESS_1108931] through systemic inflammation.2 HFpEF in p atients  with obes ity is associated 
with decreased health -related quality of life, worse heart failure symptoms, greater systemic 
inflammation and lower exercise capacity compared to HFpEF patients without obesity.31 This 
supports that obesity -related HFpEF should be treated as a specific entity, and that development of 
treatments that can promote a weight loss in this patient population is warranted .  
Semaglutide 2.4 mg once weekly  has demonstrated substantial lo wering of body weight of up to 
14.9 % by [CONTACT_5875] 68  in subjects with obesity or overweight (NN9536 STEP programme).  
To explore if a structural and functional cardiac effect can be seen, an exploratory 
echocardiographic substudy is planned only in a  subset  of subjects  to limit subject  burden.  
The aim of the present trial is to investigate the effects of semaglutide 2.4 mg on symptoms, 
physical function, health -related quality of life, and weight -loss in a population with obesity -related  
HFpEF.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 13 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  14 of 88 
 
2.2 Background  
Heart Failure with Preserved Ejection Fraction  
Heart failure (HF) is a haemodynamic disorder where the heart fails to keep up with the circulatory 
demands of the body (HFrEF), or does so at the expense of raised left ventricular filling pressures 
(HFpEF).32 HFpEF is a clinical syndrome of heart failure symptoms combined with normal or near -
to-normal LVEF and increased left ventricular filling pressures. The increased pressure can be 
measured by [CONTACT_803298]. Other echocardiographic 
findings include both structu ral and functional changes as part of diagnosing HFpEF, and left 
ventricular diastolic dysfunction (abnormal relaxation) is a key defining feature of HFpEF.[ADDRESS_1108932] decades and is now more frequ ent than heart 
failure with reduced ejection fraction (HFrEF).35-[ADDRESS_1108933] of obesity on HFpEF is probably due to a combination of mechanical 
mechanisms, volume overload, endocrine -, metabolic - and cellular signalling together with an 
altered inflammatory status.30 The aggregate of these fa ctors ultimately lead to cardiomyocyte 
dysfunction  and impaired diastolic function of the heart, while contractility is preserved. More than 
83% of patients with HFpEF are found to have either overweight or obesity.[ADDRESS_1108934] to lifestyle intervention for 
individuals with obesity -related HFpEF in order to achieve and sustain a clinically relevant weight 
loss, to improve complications and health -related quality of life.  
2.3 Benefit -risk assessment  
Main benefits and risks are described in the below sections. More detailed information about the  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 14 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  15 of 88 
 
known and expected benefits and risks and reasonably expected adverse events of semaglutide may 
be found in the IB29 or any update hereof . 
2.3.1 Risk assessment  
Potential risk of 
clinical significance  Summary of data/rationale for risk  Mitigation strategy  
Trial treatment(s)  
Gastrointestinal 
adverse event (AE)  Consistent with findings with other GLP -[ADDRESS_1108935] 
frequently reported gallbladder events in the 
phase 2 weight management trial (NN9536 -
4153) and were in a few instances co -reported 
with event adjudication committee confirmed 
acute pancreatitis.  If cholelithiasis is suspected, 
appropriate clinical follow -up is to be 
initiated at the investigator’s discretion.  
Acute pancreatitis  Acute pancreatitis has been observed with the 
use of GLP -[ADDRESS_1108936] should be 
discontinued in case of suspi[INVESTIGATOR_803277] 7.1. 
Medullary thyroid 
cancer (MTC) (based 
on non -clinical data)  Proliferative thyroid C -cell changes were seen 
in the mouse and rat carcinogenicity studies 
after daily exposure to semaglutide for 2 years. 
No hyperplasia was observed in monkeys after 
52 weeks exposure up to 13 -fold above the 
clinical plasma exposure at 2.4 mg/week. In 
clinical trials with semaglutide, there have been 
no clinically relevant changes in calcitonin 
levels. The C -cell changes in rodents are 
mediated by [CONTACT_17978] -1 receptor, which is not 
expressed in the normal human thyroid. 
Accordingly, the ri sk of GLP -1 receptor -
mediated C -cell changes in humans is low.  Exclusion criteria related to medical 
history of multiple endocrine neoplasia 
type 2 (MEN2) or MTC have been 
implemented.  
Pancreatic cancer  There is currently no support from non -clinical 
studies, clinical trials or post -marketing data 
that GLP -1 RA based therapi[INVESTIGATOR_803278], but pancreatic cancer has 
been classified as a potential class risk of GLP -1 
RAs by [CONTACT_16089] (EMA).  Subjects with a histo ry of malignant 
neoplasms within the past [ADDRESS_1108937] an increased 
risk of infection or a more severe progression of 
infection when treated with s.c. semaglutide.  Detailed information about the known 
risks for s.c. semaglutide can be found 
in the investigator’s brochure and 
summary of product characteristics.  
Trial procedures  
Cubital haematoma  Venous laboratory samples drawn at screening 
and selected visits may be associated with slight 
discomfort and complicated by [CONTACT_803299].  The number of blood samples have 
been reduced to the extent possible.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 15 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108938] enrolment  
in countries where the COVID -19 
pandemic is evaluated to be sufficiently 
under control  
Other  
Pregnancy and fertility 
(based on non -clinical 
data)  Studies in animals have shown reproductive 
toxicity. There is limited data from the use of 
semaglutide in pregnant women.  Semaglutide should not be used during 
pregnancy. Exclusion and 
discontinuation criteria related to 
pregnancy have been implemented.  
2.3.2 Benefit assessment  
Subjects will be treated with a regimen anticipated to be better than or equal to the weight 
management they receive at the time of entry into the trial. Results from the phase 3a weight 
management programme (NN9536, STEP)  demonstrated t hat s.c. 2.[ADDRESS_1108939] of the trial in 
order to minimize the risks and inconveniences of participation in the trial. The safety profile for 
semaglutide generated from the clinical and non -clinical dev elopment programme has not revealed 
any safety issues that would prohibit administration of semaglutide 2.4 mg. The results of the phase 
3a weight management  programme  (NN9536 , STEP ) indicate that semaglutide provides a clinically 
meaningful weight loss th at will provide benefit and is expected to relieve symptoms and improve 
physical function. The anticipated benefits from healthy lifestyle counselling will include all 
subjects participating in this trial.  
Considering the measures taken to minimise risk to  subjects participating in this trial, the potential 
risks identified in association with semaglutide are justified by [CONTACT_803300] -related HFpEF.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 16 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108940] of care, in subjects with obesity -related  HFpEF regarding:  
 Heart failure outcomes  
 Change in medicati ons 
 Change in biomarkers of myocardial strain  
 Echocardi ographic parameters  of heart failure (in a subset of subjects)  
Primary estimand  
The estimand will quantify the average change from baseline in KCCQ clinical summary score  and 
body wei ght of semaglutide s.c. 2.[ADDRESS_1108941] of 
care, after 52 weeks, in all randomised subjects regardless of adherence to randomised treatment 
(“treatment policy” estimand).  
The handling of intercurrent events with respect to data collection and analysis is specified in 
Table  3-1 for the primary endpoint s. Apart from the listed examples of intercurrent events, missing 
data will occur due to  non-CV deaths (KCCQ clinical summary score),  all death s (body weight) , 
withdrawn consent, loss to follow -up, or continued follow -up without endpoint evaluation.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 17 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  18 of 88 
 
Table  3-1: Handl ing of intercurrent events for the primary endpoint s 
Intercurrent event  Data collection  Data analysis  
Temporary discontinuation of trial 
treatment  Subjects will be followed, and data 
collected after intercurrent events  Primary estimand:  Data 
collected after intercurrent events 
used in analysis in line with a 
treatment -policy strategy  
 
CV deaths will be incorporated 
into the KCCQ clinical summary 
score by [CONTACT_803301]* for KCCQ clinical 
summary score  N/A 
* as determined by [CONTACT_803302] -minute walking distance will follow the strategy for KCCQ clinical summary score.  
For the hierarchical composite endpoint , the intercurrent event of CV death will be handled as part 
of the endpoint.  
3.2 Primary, secondary and exploratory endpoint(s)   
3.2.1 Multiple primary endpoints  
Endpoint title  Time frame  Unit 
Change in KCCQ clinical summary 
score (see Section 8.1) From baseline (week 0 ) to end of 
treatment (week 52) Score (no unit, range; 0 -100) 
Change in body weight  From baseline (week 0) to end of 
treatment ( week  52)  % 
3.2.2 Secondary endpoints  
[IP_ADDRESS]  Confirmatory secondary endpoints  
Endpoint title  Time frame  Unit 
Change in six -minute walking distance  From baseline (week  0) to end of 
treatment (week 52)  Metres  
Hierarchical composite of:  
Time to all -cause death,  
number of heart failure events requiring 
hospi[INVESTIGATOR_803275],  
time to first heart failure event 
requiring hospi[INVESTIGATOR_803279],  
difference at least [ADDRESS_1108942] 5 in KCCQ clinical 
summary score change from baseline to 
52 weeks,  From baseline (week 0) to end of 
study (week 57)  Total wins for each treatment 
group  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 18 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108943] 30 metres in six-
minute walking distance  change from 
baseline to 52 weeks  
(assessed by [CONTACT_15604])  
Change in C -Reactive Protein (CRP)  From baseline (week -2) to end of 
treatment (week 52)  Ratio to baseline (no unit)  
[IP_ADDRESS]  Supportive secondary endpoints  
Endpoint title  Time frame  Unit 
Subject achieving 10 % weight loss or 
more (Yes/No)  From baseline (week 0) to end of 
treatment ( week 52) Count of subjects  
Subject achieving 15 % weight loss or 
more (Yes/No)  From baseline (week 0) to end of 
treatment ( week 52) Count of subjects  
Subject achieving 20 % weight loss or 
more (Yes/No)  From baseline (week 0) to end of 
treatment ( week 52 ) Count of subjects  
Subject improving 5 points or more in 
KCCQ clinical summary score 
(Yes/No)  (see Section 8.1)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Subject improving 10 points or more in 
KCCQ clinical summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment  (week 52)  Count of subjects  
Change in KCCQ overall summary 
score (see Section 8.1) From baseline (week 0) to end of 
treatment (week 52)  Score (no un it, range 0 -100) 
Subject achieving threshold for 
clinically meaningful within -subject 
change in KCCQ -CSS From baseline (week 0) to end of 
treatment ( week 52)  Count of subjects  
Subject achieving threshold for 
clinically meaningful within -subject 
change in  6MWD  From baseline (week 0) to end of 
treatment ( week 52)  Count of subjects  
Change in systolic blood pressure 
(SBP)  From baseline (week -2) to end of 
treatment (week 52)  mmHg  
Change in waist circumference  From baseline (week 0) to end of 
treatment (visi t 52)  cm 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 19 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  20 of 88 
 
3.2.3 Exploratory endpoint(s)  
Endpoint title  Time frame  Unit 
Change in antihypertensive medication  From baseline (week 0) to end of 
treatment (week 52) Category (no unit; decrease / 
no change / increase)  
Change in loop diuretic medication  From baseline (week 0) to end of 
treatment (week 52) Category (no unit, decrease / 
no change / increase)  
Change in NT -proBNP  From baseline (week -2) to end of 
treatment (week 52) pg/mL  
Change in EQ -5D-5L score   From baseline (week 0) to end of 
treatment (week 52) Score (no unit, range per item; 
1-5)  
Subject worsening 5 points or more in 
KCCQ clinical summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Subject worsening  10 points or more in 
KCCQ clinical summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Subject improving 5 points or more in 
KCCQ overall summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52 ) Count of subjects  
Subject improving 10 points or more in 
KCCQ overall summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Subject worsening 5 points or more in 
KCCQ overall summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Subject worsening 10 points or more in 
KCCQ overall summary score 
(Yes/No)  From baseline (week 0) to end of 
treatment (week 52)  Count of subjects  
Change in subscales of KCCQ (total 
symptom score, p hysical limitations 
score, social limitations score, and 
health -related quality of life)  From baseline (week 0) to end of 
treatment (week 52) Score (no unit, range 0 -100) 
Subject experiencing deterioration in 
NYHA Class (Yes/No)  From baseline (week -2) to  end of 
treatment (week 52)  Count of subjects  
Time to first heart failure event 
(hospi[INVESTIGATOR_803280])  From baseline (week 0) to end of 
treatment (week 52)  Days  
Imaging sub study  
Change in left atrial volume  From baseline (week 0) to end of 
treatment (week 52) Ratio to baseline (no unit)  
Change in left ventricular (LV) filling 
pressure (diastolic function) (E/e´)  From baseline (week 0) to end of 
treatment (week 52) Ratio to baseline (no unit)  
Change in global longitudinal strain  From baseline (week 0) to end of 
treatment (week 52) % 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 20 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  21 of 88 
 
4 Trial design  
4.1 Overall design  
This is a 52-week, randomised, placebo -controlled, double blind, multi -centre clinical trial 
comparing semaglutide s.c. 2.4 mg with placebo in subjects with obesity -related  heart failure with 
preserved ejection fraction.  
Eligible subjects will be randomised in a 1:[ADDRESS_1108944] of care ( Figure  4-1). 
The trial includes a screening visit to assess the subject’s eligibility followed by  a randomisation  
visit. A period of [ADDRESS_1108945] every 8th week until end of 
treatment (week 52). Follow -up period is [ADDRESS_1108946] 180 subjects undergoing echocardiography at the end of treatment.   
Randomisation  will be stratified by [CONTACT_803303] (BMI <35.0 and B MI ≥35.0).  
Figure  4-[ADDRESS_1108947] of subjects with obesity (≥ BMI 30.0 kg/m2) and HFpEF 
(symptoms of HF, signs of HF, LVEF ≥ 45 %, and relevant structural heart disease and/or diastolic 
dysfunction).54 The trial population is chosen to optimise the likelihood of clinical benefit of weight 
loss by [CONTACT_803304] b ehind their HF is likely to be obesity.  
Although T2D is prevalent in the HFpEF population, it has been decided to exclude this group of 
subjects from the trial in order to get a homogenous study population.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 21 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108948] (6MWT) is 
unaware of other assessments that could reveal treatment group.   
4.3 Justification for  dose  
Results from the phase 3a weight management  programme (NN9536, STEP) showed that a 
maintenance dose of semaglutide s.c. 2.4 mg once  weekly clinically meaningfully reduces body 
weight while displaying an acceptable tolerability profile. Since weight loss is expected to be part of 
symptom relief and better physical function in HFpEF patients, a large weight loss is attractive also 
in patients with obesity -related  HFpEF. The once  weekly dosing is anticipated to ease the burden of 
drug admin istration in clinical practice. Subjects will initiate treatment with a once -weekly dose of 
0.25 mg and follow a fixed dose escalation regimen, with dose increase every 4 weeks (to doses of 
0.5, 1.0, 1.7 mg/week), until the  2.4 mg /week  maint enance  dose is reached after [ADDRESS_1108949] completed the trial if he/s he has completed all phases of the trial 
including the last visit.  
The end of the trial is defined as the date of the last visit of the last subject in the trial globally.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 22 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  23 of 88 
 
5 Trial population  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1 Inclusion criteria  
 Subjects are eligible to be included in the trial only if all the following criteria apply:  
1. Informed consent obtained before any trial -related activitie s. Trial -related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial.  
2. Male or female, age above or equal to 18 years at the time of signing informed consent.  
3. BMI ≥ 30.0 kg/m2. 
4. NYHA Class II -IV. 
5. LVEF ≥ 45 % at screening.  
6. No hospi[INVESTIGATOR_803281] (visit 1) and randomisation (visit 2). 
7. Able to perform the 6MWT at screening with a minimum distance of 100 metres.  
8. KCCQ clinical summary score < [ADDRESS_1108950] one of the following:  
a. Mean pulmonary wedge pressure ≥ 15 mmHg or left ventricular end diastolic 
pressure (LVEDP) ≥ [ADDRESS_1108951] or 
pulmonary artery (PA) diastolic pressure measured by [CONTACT_803305] ≥ 15 
mmHg or pulmonary wedge pressure or LVEDP ≥ 25 mmHg documented during 
catheterisation at exercise.  
b. If BMI < 35.0: NT -proBNP ≥ 220 pg/mL (for patients with sinus rhythm) or NT -
proBNP ≥ 660 pg/mL (for patients with persistent/permanent atrial fibr illation); if 
BMI ≥ 35.0: NT-proBNP  ≥ 125 pg/mL (for patients in sinus rhythm) or NT -proBNP  
≥ 375 pg/mL (for patients with persistent/ permanent atrial fibrillation) at screening 
(NT-proBNP analysed by [CONTACT_2237]) in combination with at least  one of 
the following (documented by [CONTACT_803306] 12 months prior to or at 
screening):  
i. Septal é < 7 cm/ sec or lateral é < 10 cm/sec or average E/é ≥ 15  
ii. PA systolic pressure > 35 mmHg  
iii. Left atrial (LA) enlargement (LA width ≥ 3.8 cm or LA length ≥  5.0 cm or 
LA area ≥ 20 .0 cm2 or LA volume ≥ 55 mL or LA volume index ≥ 29 
mL/m2) 
iv. LV hypertrophy with septal thickness or posterior wall thickness ≥ 1.2 cm  
c. Hospi[INVESTIGATOR_36233] a primary diagnosis  of decompensated heart failure which 
required  intravenous (IV) loop diuretic treatment , within the previous [ADDRESS_1108952] two of the following (documented by [CONTACT_803307] 12 months prior to or at screening):  
i. Septal é < 7 cm/sec or lateral é < 10 cm/sec or average E /é ≥ 15  
ii. PA systolic pressure > 35 mmHg  
iii. LA enlargement (LA width ≥ 3.8 cm or LA length ≥ 5.0 cm or LA area ≥ 
20.0 cm2 or LA volume ≥ 55 mL or LA volume index ≥ 29 mL/m2) 
iv. LV hypertrophy with septal thickness or posterior wall thickness ≥ 1.2 cm  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 23 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108953]  30 days prior to screening  
5.2 Exclusion criteria  
Subjects are excluded from the trial if any of the following criteria apply:  
Cardiovascular -related:  
1. Myocardial infarction, stroke, hospi[INVESTIGATOR_803282] e, unstable angina pectoris or 
transient ischemic attack within 30 days prior to the day of screening.  
2. Systolic blood pressure >  160 mmHg at screening.  
3. Planned coronary, carotid or peripheral artery revascularization.  
4. Any other condition judged by [CONTACT_803308] (such as 
heart failure due to restrictive cardiomyopathy or infiltrative conditions (e.g. amyloidosis), 
hypertrophic obstructive cardiomyopathy, primary pulmonary arterial hypertension, chronic 
obstructive pulmo nary disease, right heart failure due to pulmonary disease, complex congenital 
heart disease, anaemia , or more than moderate heart valve disease).  
Obesity -related:  
5. Bariatric surgery prior to screening or planned bariatric surgery within the trial time cour se. 
6. A self -reported change in body weight > 5 kg (11 lbs) within 90 days before screening 
irrespective of medical records . 
Glycemia -related:  
7. HbA1 c ≥ 6.5 % (48 mmol/mol) based on latest available value from medical records, no older 
than 3 months or if unavailable at local measurement at screening.  
8. History of type 1 or type 2 diabetes (history of gestational diabetes is allowed).  
9. Treatment with any G LP-[ADDRESS_1108954] within 90 days prior to the day of screening.  
General health and safety:  
10. Personal or first -degree relative(s) history of multiple endocrine neoplasia type [ADDRESS_1108955](s) or related products.  
16. Participation in any clinical trial of an approved or non -approved  device for the treatment of 
heart failure or obesity within [ADDRESS_1108956] -feeding or intends to become pregnant or is of child -bearing 
potential and not using a highly effective contraceptive method.  
19. Major surgery scheduled for the duration of the trial, affecting walking ability in the opi[INVESTIGATOR_13046].  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 24 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  25 of 88 
 
20. Any disorder, including severe psychiatric disorder, suicidal behavio ur within 90 days before 
screening, and suspected drug abuse, which in the investigator´s opi[INVESTIGATOR_803283]´s safety or compliance with the protocol.   
The criteria will be assessed at the investigator’s discretion unless otherwise stated.  
5.[ADDRESS_1108957] should be offered individualised healthy lifestyle counselling (including 
diet and physical activity).  
5.4 Screen failures  
Screen failures are defined as subjects who consent to participate in the clinical tria l but are not 
eligible for participation according to inclusion/exclusion criteria. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure subjects to meet 
requirements from regulatory authorities. Minimal  information includes  demography, screen failure 
details  and eligibility criteria.  
A screen failure session must be made in the interactive web response system (IWRS).  
Individuals who do not meet the criteria for participation in this trial are allowed to be rescreened  
once . If the subject has failed one of the inclusion criteria or fulfilled one of the exclusion criteria 
related to laboratory parameters, re -sampling is not allowed. However, in case of technical issues 
(e.g. haemolysed or lost), re -sampling  is allowed for the affected parameters.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 25 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  26 of 88 
 
6 Treatments  
6.1 Treatments administered  
Investigational medicinal products (IMP)  
Table  6-[ADDRESS_1108958] name : 
 [CONTACT_803328] D 0.5 
mg/mL DV3396  0.25 mg  Solution for 
injection  s.c. Once -weekly  0.5 mL DV3396 
pen-injector  
Semaglutide D 1.0 
mg/mL DV3396  0.5 mg  Solution for 
injection  s.c. Once -weekly  0.5 mL DV3396 
pen-injector  
Semaglutide D 2.0 
mg/mL DV3396  1.0 mg  Solution for 
injection  s.c. Once -weekly  0.5 mL DV3396 
pen-injector  
Semaglutide placebo 
Ia NA Solution for 
injection  s.c Once -weekly  0.5 mL DV3396 
pen-injector  
Semaglutide D 2.27 
mg/mL DV3396  1.7 mg  Solution for 
injection  s.c. Once -weekly  0.75 mL 
DV3396 pen -
injector  
Semaglutide D 3.2 
mg/mL DV3396  2.4 mg  Solution for 
injection  s.c. Once -weekly  0.75 mL 
DV3396 pen -
injector  
Semaglutide placebo 
Ib NA Solution for 
injection  s.c. Once -weekly  0.75 mL 
DV3396 pen -
injector  
 The investigator must document that directions for use are given to the subject verbally and in 
writing  as a direction for use (DFU) document,  at the first dispensing visit  (as specified in the 
flowch art). 
 It is recommended that the investigator consults Novo Nordisk in case of persistent deviations 
from the planned escalation regimen.  
 Dose escalation of semaglutide/placebo should take place during the first 16 weeks after 
randomisation as described in Table  6-2. All subjects should aim  at reaching the 
recommended target dose of semaglutide 2.4 mg once -weekly or placebo but individual 
escalation and dosing are allowed (see later in this section).
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 26 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  27 of 88 
 
Table  6-2 Dose escalation and maintenance of  semaglutide/semaglutide placebo  
Trial product name  [CONTACT_803329] D 0.5 mg/mL DV3396 or 
semaglutide placebo Ia  0.25 mg  0.5 mL DV3396 pen -injector  4 weeks  
Semaglutide D 1.0 mg/mL DV3396 or 
semaglutide placebo Ia  0.5 mg  0.5 mL DV3396 pen -injector  4 weeks  
Semaglutide D 2.0 mg/mL DV3396 or 
semaglutide placebo Ia  1.0 mg  0.5 mL DV3396 pen -injector  4 weeks  
Semaglutide D 2.27 mg/mL DV3396 or 
semaglutide placebo I b 1.7 mg  0.75 mL DV3396 pen -injector  4 weeks  
Maintenance period  
Semaglutide D 3.2 mg/mL DV3396 or 
semaglutide placebo I b 2.[ADDRESS_1108959] semaglutide/placebo once  weekly at the same day of the week 
(to the extent possible) throughout the trial.  
Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective 
of meals.  
If a single dose of trial product is missed, it should be administered as soon as noticed, provided the  
time to the next scheduled dose is at least 2 days (48 hours). If a dose is missed and the next 
scheduled dose is less than 2 days (48 hours) away, the subject should not administer a dose until 
the next scheduled dose. A missed dose should not affect the  scheduled dosing day of the week.  
If ≥ [ADDRESS_1108960] should be encouraged to 
recommence the treatment if considered safe as per the investigator ’s discretion and if the subject 
does not meet any of the discon tinuation criteria ( 7). The trial product should be continued as early 
as the situation allows. The missed doses should not affect the scheduled dosing day of the week. 
The start dose for re -initiation of trial pro duct is at the investigator’s discretion but the following 
guidance can be used:   
 If ≤3 consecutive doses are missed, once -weekly regimen can be resumed as prescribed without 
dose reduction  
 If 4-5 consecutive doses are missed, it is recommended to resume t reatment at 1.0 mg for 4 
weeks, and then escalate to 2.4 mg, using 1.7 mg as the intermediate dose for 4 weeks  
 If ≥[ADDRESS_1108961] is associated with unacceptable AEs or due to 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 27 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108962] one attempt to re -escalate to the recommended target dose of 2.4 mg 
once  weekly.  
Date and dose  are to be reported in the electronic case report form ( eCRF) when trial product dose 
is initiated or changed (reason for change should also be reported).  
Auxiliary supplies  
Auxiliary supplies will be provided in accordance with the trial materials manual (TMM ) and  
Table  6-3. 
Table  6-3 Auxiliary supplies provided by [CONTACT_3454] A/S  
Auxiliary supply  Details  
Direction for use (DFU)  DFU for DV3396 pen -injector  
Not included in the dispensing unit and to be handed out separately  
Needle  The DV3396 pen -injector comes with an integrated and hidden needle of 6 mm in 
length (29G), therefore no needles are required to be used with this pen -injector  
6.1.1 Medical devices  
Information about the DV3396 pen -injector may be found in the IB29 and any updates hereof.  
Information about the use of the drug -device combination products can be found in the DFU.   
Training in the DV3396 pen -injector  
Site staff will train subjects according to the flowchart (Secti on 1.2). Novo Nordisk will train the 
site staff and only trained site staff can be allocated the task to train and supervise subjects. All 
training must be documented.  
The following should be emphasi sed during training of subjects : 
 use of the pen -injector (according to instruction guidelines given in the DFU)  
 subjects should be informed to follow label instructions for storage and in -use time 
conditions descriptions on the labels  and in the TMM . In-use time starts if removed from the 
refrigerator.  
The investigator must document that DFU are given to the subjects orally and in writing at the first 
dispensing visit  and that subjects are trained . Training must be repeated as specified in the flowchart 
(1.2) and, if needed, during the trial at regular intervals in order to ensure correct use of the pen-
injector . Training is the responsibil ity of the investigator or delegate.  
The first dose of trial product must be taken on the day of randomisation  (V2) at the clinical site by 
[CONTACT_6270]-administration under supervision by [CONTACT_43065].  
6.2 Preparation/handling/storage/accountability  
Only subjects randomised to treatment may use trial product and only delegated site staff may 
supply or administer trial product.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 28 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  29 of 88 
 
 Acceptable temperature ranges and conditions for storage and handling of each trial product 
when not in use and when in use are des cribed in the TMM.  
 Each site will be supplied with enough trial products for the trial on an ongoing basis. Trial 
product will be distributed to the sites according to screening and randomisation.  
 The investigator or designee must confirm that appropriate temperature conditions have been 
maintained during transit for all trial products received, and that any discrepancies are 
reported and resolved before use of the trial products.  
 All trial products must be stored in a secure, controlled, and monitored (man ual or automated) 
area in accordance with the labelled storage conditions with access limited to the investigator 
and delegated site staff.  
 The investigator must inform Novo Nordisk immediately if any trial product has been stored 
outside specified conditi ons. The trial product must not be dispensed to any subject before it 
has been evaluated and approved for further use by [CONTACT_3454]. Additional details 
regarding handling of temperature deviations can be found in the TMM.  
 The investigator or designee is responsible for drug accountability and record maintenance (i.e. 
receipt, accountability and final disposition records).  
 The investigator or designee must instruct the subject in what to return at next visit.  
 Drug accountability should be performed on a pe n level and must be documented in the IWRS.  
 The subject must return all used, partly used and unused trial product including empty 
packaging materials during the trial as instructed by [CONTACT_093].  
 Destruction of trial products can be performed on a n ongoing basis and will be done according 
to local procedures after accountability is finalised by [CONTACT_41138].  
 All returned, expi[INVESTIGATOR_17945] (for technical complaint samples, see Section  
10.510.5) must be stored separately from non -allocated trial products. No temperature 
monitoring is required.  
 Non-allocated trial products including expi[INVESTIGATOR_41073], at the latest at closure of the site.  
6.2.[ADDRESS_1108963]’s home  
For selected countries and if  permitted by [CONTACT_427], the investigator may offer to send trial 
product and auxiliaries from the trial site or pharmacy to the subject’s home by [CONTACT_17997].  
The process for sending trial product from the trial site or pharmacy to a subject’ s home is 
described in the “Trial site/pharmacy instruction for shipment of trial product to patients’ homes” 
document. The document contains detailed instructions for preparing packaging and setting up the 
pi[INVESTIGATOR_9696]-up of trial product, handover of trial produ ct from the trial site or pharmacy staff to the courier, 
required temperature monitoring of trial product, delivery to and receipt of trial product by [CONTACT_1560]. The process for returning trial product to the trial site or pharmacy by [CONTACT_17998].  
Investigators, trial site/pharmacy staff and subjects who will be involved in shipment of trial 
product to the subject’s home will be adequately trained in this process.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 29 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  30 of 88 
 
6.3 Measures to minimise bias: Randomisation and blinding  
All su bjects will be centrally screened and randomised using an IWRS and assigned to the next 
available treatment according to randomisation schedule. Trial product will be dispensed/allocated 
at the trial visits summarised in the flowchart.  
To ensure sufficient  statistical power for subgroup analyses according to BMI, random isation will 
be stratified into two subgroups (BMI <35.0 and BMI ≥35.0) and a maximum of 50% of subjects 
will be enforced on the lower BMI subgroup.  
The active drug and placebo are visually identical for the following trial products:  
 Semaglutide D 0.5 mg/mL , Semaglutide D 1.0 mg/mL, Semaglutide D 2.0 mg/mL DV3396  and  
Semaglutide placebo Ia  
 Semaglutide D 2.27 mg/mL, Semaglutide D 3.2 mg/mL and Semaglutide placebo Ib  
The IWRS is used for blind -breaking. In case of an emergency, the investigator has the sole 
responsibility for determining if unblinding of a subjects’ treatment is warranted. Subject safety 
must always be the first consideration in making such a determina tion. If the investigator decides 
that unblinding is warranted, the investigator should make every effort to contact [CONTACT_803309] a subjects’ treatment unless this could delay emergency treatment of the subject. 
If a subject’s treatment  is unblinded, Novo Nordisk (Global Safety department) must be notified 
within [ADDRESS_1108964] print the "code  break 
confirmation" notification generated by [CONTACT_8784], sign and date the document. If IWRS is not 
accessible at the time of blind break, the IWRS helpdesk should be contact[INVESTIGATOR_530]. Contact [CONTACT_803310] I . 
6.[ADDRESS_1108965] be documented.  Compliance can be assessed by [CONTACT_197649]:  
 Drug accountability information; visual inspection of pen -injectors   
 Questioning  of subjects about missed doses and current treatment dose at every visit  
 
Information on treatment dose and periods >[ADDRESS_1108966] be recorded in the eCRF.  
6.5 Concomitant medicati on 
Initiation of any GLP -1 RA should be avoided during the trial. The investigators are encouraged to 
ensure constant ongoing optimisation of the treatment of any comorbidity.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 30 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108967] be recorded in the eCRF:  
 To treat or prevent HF or cardiovascular diseases (e.g. antihypertensives, diuretics, lipid -
lowering agents, anticoagulants, aspi[INVESTIGATOR_803284]).  
 To treat overweight or obesity.  
 To treat a serious adverse event ( SAE ) or medication which may provide further information on 
the SAE i.e. alternative aetiology.  
 To treat diabetes and diabetes complications (for subjects who develop diabetes during the 
trial).  
 COVID -19 vaccine  
The information collected for each concomitant medication includes start date and stop date or 
continuation, dose (only to be collected for loop diuretics at selected visits  as outlined in the 
flowchart ) and related AE n umber when applicable.  
Changes in concomitant medication listed above must be recorded at each visit.  If a change is due to 
an SAE,  then this must be reported according to Section 8.3. 
During the trial, subjects should not initiate any weight management drugs or treatment which is not 
part of the trial procedures. If such treatment is initiated, the subjects should be instructed to stop 
the treatment.  
6.[ADDRESS_1108968] should  be treated at the discretion of the investigator.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 31 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108969]  
discontinuation/withdrawal  
Treatment of a subject may be discontinued at any time during the trial at the discretion of the 
investigator  for safety, behavioural, compliance or administrative reasons.  
Efforts must be made to have subjects, who discontinue trial product, to continue in the trial. 
Subjects must be educated about the continued scientific importance of their data, even if they 
discontinue trial product. Only subjects who withdraw consent will be considered as withdrawn 
from the trial.  
Temporary or permanent discontinuation of treatment with trial product will not lead to withdrawal 
from the trial.  
7.1 Discontinuation of trial trea tment  
 Discontinuation of treatment can be decided by [CONTACT_18003].  
 Subjects who discontinue trial product should be encouraged to continue with the scheduled 
visits and assessments to ensure continued healthy lifestyle counselling and data collection.  
 If the subject does not wish to attend the scheduled clinic visits, efforts should be made to have 
the visits converted to phone contacts. However, all effort should be made to have the subject 
attend at least the  ‘end-of-treatment  visit’ (V11) containing the final data collection of 
primary and confirmatory secondary efficacy endpoints and participate in the ‘end-of-trial 
phone  contact’  (P12).  
 The ‘end -of-trial’ phone contact  [CONTACT_803311] 5 weeks after the ‘end-of-treatment ’ visit, to 
ensure the safety of the subject. If the subject has discontinued trial product > 5 weeks prior to 
the ‘end -of-treatment’ visit, and the requirements for the follow -up period prior to the ‘end -
of-trial’ phone contact  [CONTACT_803312], then the ‘end -of-trial’ phone contact  [CONTACT_803313] ‘end-of-treatment’ visit.  
 If the subject is unwilling  to attend the ‘end -of-treatment’ and/or ‘end -of-trial’ phone contact , 
information about the attempts to follow up with the subject must be d ocumented in the 
subject’s medical record.  
The trial product must be discontinued, if any of the following applies for the subject:  
1. Safety concern as judged by [CONTACT_093]  
2. Suspi[INVESTIGATOR_36194]  
3. Pregnancy  
4. Intention of becoming pregnant  
5. Simul taneous use of an approved or non -approved investigational medicinal product in another 
clinical trial . However, simultaneous participation in a ‘COVID -19 vaccine trial’ is allowed 
without discontinuing Novo Nordisk trial product . 
If acute pancreatitis is suspected appropriate actions should be initiated, including local 
measurements of amylase and lipase (see 10.3.3  for report ing).  
Subjects meeting discontinuation of trial product criterion no. [ADDRESS_1108970] if the 
Atlanta criteria55 are not fulfilled and thus, the suspi[INVESTIGATOR_244166]. Trial 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 32 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108971], if 
the criteria are no longer met (Section 7.1.1 ). 
The primary reason for permanent discontinuation of trial product must be specified in the end -of-
treatment -form in the eCRF, and final drug accountability must be performed.  
7.1.[ADDRESS_1108972] is allowed to be resumed , the guide for missed doses 
should be followed  (Section 6.1). Similarly, a subject who discontinues trial product on their own 
initiative should be encouraged to resume trial product (Section 6.1). 
If a ‘treatment status’ session previously has been made in IWRS to indicate discontinuation of 
treatment, a new “treatment status” session must be made to resume trial product.  
In case of suspi[INVESTIGATOR_36194], the trial product should promptly be interrupted; however 
a ‘treatment status’ session to discontinue treatment should not be made in  IWRS  before diagnosis 
of acute pancreatitis is confirmed. Appropriate actions  should be initiated, including local 
measurement of amylase and lipase (see appendix 3 (Section 10.3) for AE reporting).  
If acute pancreatitis is c onfirmed, treatment with trial product should not be restarted, and a 
‘treatment status’ session should be made in IWRS to indicate discontinuation of trial product. If the 
Atlanta criteria54 are not fulfilled, and thus, the suspi[INVESTIGATOR_244166], 
treatment with trial product can be resumed . 
7.2 Subjec t discontinuation /withdrawal  from the trial  
A subject may withdraw consent at any time at his/her own request . 
If a subject withdraws consent, the investigator must ask the s ubject if he/she is willing, as soon as 
possible, to have assessment performed according to the ‘end of treatment’ visit (V11) . See the 
flowchart for data to be collected.  
Final drug accountability must be performed even if the subject is not able to come to the site. A 
treatment status session must be made in the IWRS to indicate discontinuation of treatment.  
If the subject withdraws consent, Novo Nordisk may retain and con tinue to use any data collected 
before such a withdrawal of consent.  
Publicly available data sources should also be searched for withdrawn subjects to establish vital 
status (unless prohibited by [CONTACT_1295]).  
If a subject withdraws from the trial, he /she may request destruction of any samples taken and not 
tested, and the investigator must document this in the medical record.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 33 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108973] is not obliged to give his/her reason(s) for withdrawing, the investigator must 
make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where 
the reasons are obtained, the primary reason for withdrawal must be specified in the ‘end -of-trial’ 
form in the eCRF.  
7.2.[ADDRESS_1108974] fails to return to the site for a required visit:  
 The site must attempt to contact [CONTACT_803314]/or should continue in the trial.  
 Before a subject is deemed lost to follow -up, the investigator or designee must make every 
effort to regain contact [CONTACT_1155] (where possible, at least three telephone calls and, if 
necessary, a certified letter to the subject's last known mailing address or local equivalent 
methods). These contact [CONTACT_9300]'s source document.  
 Should the subject continue to be unreachable, he/she will be considered to have withdrawn 
from the trial with a primary reason of `lost to follow -up'. 
 If establishing direct contact [CONTACT_160582], vital status (dead or alive) should be obtained. 
Publicly available data sources should also be searched at end of trial (unless prohibited by 
[CONTACT_1295]).  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 34 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  35 of 88 
 
8 Trial assessments and procedures  
 The following sections describe the assessments and procedures, while their timing is 
summarised in the flowchart  and Appendix 2  (Section  10.2). 
 Informed consent must be obtained before any trial related activity, see Section  10.1.3 10.1.3 . 
 All screening evaluations must be completed and reviewed to confirm that potential subje cts 
meet all inclusion criteria and none of the exclusion criteria.  
 The investigator will maintain a screening log to record details of all subjects screened and to 
confirm eligibility or record reason for screen failure, as applicable.  
 At screening, subje cts will be provided with a card stating that they are participating in a trial 
and giving contact [CONTACT_364064].  
 Adherence to the trial design requirements, including those specified in the flow chart, is 
essential and required for trial conduct.  
 Review of ECG, laboratory reports and echocardiography must be documented either on the 
documents or in the subject's medical records.  
 Results of pregnancy testing must be documented in the subject's med ical records.  
 Repeat samples may be taken for technical issues and unscheduled samples or assessments may 
be taken for safety reasons. Please refer to Appendix 2 , Section  10.2 for further details on 
laboratory samples.  
8.1 Efficacy assessments  
Planned time points for all efficacy assessments are provided in the flowchart Section 1.2.  
8.1.1 Body measurements  
Body weight  should be measured without shoes and only wearing light clothing. It should be 
measured on a digital scale and recorded in kg or lb (one decimal with a precision of 0.1 kg or lb) 
using preferable the same scale throughout the trial. The scale must be cali brated according to 
manufacturer’s recommendation.  
Height  is measured without shoes in centimetres or inches (one decimal with a precision of 0.1 
centimetres or inches). At screening BMI will be calculated by [CONTACT_803315] n no. 3.  
Waist circumference  is defined as the abdominal circumference located midway between the 
lower rib margin and the iliac crest. Measure ment  must be obtained in standing position with a non -
stretchable measuring tape and to the nearest cm or inch.  
The tape should touch the skin but not compress soft tissue and twists in the tape should be avoided. 
The subject should be asked to breathe normally. The same measuring tape should be used 
throughout the trial. The measuring tape will be provided by [CONTACT_244183].  
8.1.[ADDRESS_1108975] transcribe directly into a site -pad/web -solution. Subject s are not all owed 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 35 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  36 of 88 
 
to answer the questions on paper.  Site staff should activate and verify completion of the 
questionnaires (as specified in the TrialMax Slate® and TrialManager® Site User Guid e). 
The following electronic patient reported outcome ( ePRO) questionnaires will be used:  
Patient Global Impression of Status (PGI -S) for KCCQ version 1.0.  
Patient Global Impression of Change (PGI -C) for KCCQ version 1.0.  
Kansas City Cardiomyopathy Questionnaire (KCCQ) version 2.0. 
 The KCCQ is a disease -specific health status inst rument composed of [ADDRESS_1108976] 
been independently de monstrated to be valid, reliable, and responsive to clinical change. 
Scores range from 0 to 100.56 
EuroQoL five dimensions five level (EQ -5D-5L). 
 The EQ -5D-5L will be used to estimate the impact on patients’ health -related quality of life and 
provides a description of patient’s problems by [CONTACT_53821] (descriptive system), a score for 
overall self -rated health (visual analogue scale (VAS) as well as an index score (EQ -5D-5L 
index)). EQ -5D index score range: 0 to 1 and EQ -5D-VAS: range [ADDRESS_1108977]   
Patient Global Impression of Status  (PGI -S) for 6MWT version 1.0.  
Patient Global Impression of Change (PGI -C) for 6MWT version 1.0.  
The following PRO  test will be performed:  
6-minute walk test (6MWT)  
 The 6MWT assesses the distance a subject can walk in six minutes. It is a direct and timed 
measure of walking ability, which is technically simple, reproducible, and when 
administrators are well trained, readily standardised. The goal is for the subject to walk as far 
as possible in six minutes without running.  The subject can self -pace and rest as needed as 
they traverse back and forth along a marked walkway of 66 feet (20 m) ( Figure  8-1). The 
primary outcome is the distance covered over six minutes .  
 The 6MWT must be performed in accordance with the manual provided by [CONTACT_3454].  
 
Figure  8-[ADDRESS_1108978] 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 36 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  37 of 88 
 
Planned time points for all efficacy assessments are provided in the flowchart ( 1.2).  
In order t o assess the subject’s  perception of the allocated treatment  a question regar ding this will 
be posed at the ‘end-of-treatment ’ visit. 
8.1.[ADDRESS_1108979] be performed in all subjects at the screening visit assessing only the LVEF 
to ensure agreement with inclusion criterion number 5.  
Only for subjects participating in the sub study:  
The echocardiography must be performed a s outlined  in the flowchart . The echocardiography must 
be performed in accordance with the manual from the supplier.  
8.1.[ADDRESS_1108980] the finding on the Medical  History/ 
Concomitant Illness form.  
8.2.1 Physical examinations  
 A physical examination will include assessments of signs of HF, the cardiovascular, respi[INVESTIGATOR_696], 
gastrointestinal and general appearance.  
 Investigators should pay special attention to clinical signs  related to previous serious illnesses.  
8.2.[ADDRESS_1108981] clinical practice at site, however as a minimum:  
 Vital sign assessment should be preceded by [CONTACT_2669] [ADDRESS_1108982] in a quiet 
setting without distractions (e.g. no use of television, cell phones).  
 Blood pressure and pulse rate measurements will be assessed with a completely automated 
device. Manual techniques must be used only if  an automated device is not available.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 37 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  38 of 88 
 
8.2.3 Electrocardiograms  
 12-lead ECG will be obtained as outlined in the flowchart using an ECG machine that 
automatically calculates the heart rate and measures PR and QRS intervals.   
 The investigator must perform review o f the ECG for clinically significant abnormal findings.  
8.2.4 [LOCATION_001] Heart Association (NYHA) classification  
The investigator must assess the functional status of the subject based on below:  
 Class I: No limitation of physical activity. Ordinary physical activ ity does not cause undue 
fatigue, palpi[INVESTIGATOR_332], dyspnoea.  
 Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity 
results in fatigue, palpi[INVESTIGATOR_332], dyspnoea.  
 Class III: Marked limitation of physical activity. Comfort able at rest. Less than ordinary 
activity causes fatigue, palpi[INVESTIGATOR_332], or dyspnoea.  
 Class IV: Unable to carry on any physical activity without discomfort. Symptoms of heart 
failure at rest. If any physical activity is undertaken, discomfort increases.  
8.2.[ADDRESS_1108983] be 
conducted in accordance with the flowchart and the laboratory manual.  
8.3 Adverse events and serious adverse events  
The investigator is responsible for detecting, documenting, recording and following up on all the 
events listed below:  
 SAEs  
 Following AEs irrespective of seriousness : 
o AEs leading to premature treatment discontinuation  
o AEs related to COVID -19 
Note: Suspected COVID -[ADDRESS_1108984] (antigen or 
antibody) should be reported, if available.  
o AEs requiring additional data collection (Table  8-1) 
▪ Acute pancreatitis  
▪ Medication errors   
▪ Misuse and abuse  
 AEs for adjudication  (Table  8-1): 
o Heart failure hospi[INVESTIGATOR_803285]  
o Death  
 Pregnancies  
 Obesity related surgical procedures - the procedure (e.g. bariatric surgery) must be reported as  
an AE  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 38 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  39 of 88 
 
Events for adjudication require data collection on an adjudication form. Event adjudication will be 
performed in randomised subjects and will be evaluated by [CONTACT_508097] (EAC) in a blinded manner, please refe r to Section [IP_ADDRESS] . 
Table  8-1 AEs requiring additional data collection (serious and non -serious AEs) and 
events for adjudication  
Event type   AE requiring additional data collection  Event for adjudication  
 
Acute pancreatitis  X  
Medication error  X  
Misuse and abuse  X  
Heart failure hospi[INVESTIGATOR_803286]   X 
Death   X 
A detailed description of the events mentioned in the above table can be found in Appendix 3  
(Section 10.3). 
There are four ways to identify events relevant for adjudication as described below:  
1. Investigator -reported events for adjudication: investigator selects the appropriate AE category 
relevant for adjudication (see Appendix 3 , Section 10.3.3 ).  
2. AEs reported with fatal outcome  
3. AE search (standardised screening): All AEs not reported with an AE category relevant for 
adjudication will undergo screening to id entify potential events for adjudication. Investigators 
will be notified of these events in the eCRF.  
4. EAC -identified events: Unreported events relevant for adjudication identified by [CONTACT_111421]. Investigators 
will be notified of these events in the eCRF and has the option to report the EAC -identified 
event.  
For each event relevant for adjudication an event type specific adjudication form should be 
completed in the eCRF within 14 days . 
Copi[INVESTIGATOR_111356] (EAS) as soon as 
possible and preferably within [ADDRESS_1108985] ed and saved locally until the EAS is 
ready. If no, or insufficient source documents are provided to the adjudication supplier, the 
investigator can be asked to complete a clinical narrative to be uploaded to the EAS.  
If new information becomes available f or an event sent for adjudication, it is the responsibility of 
the investigator to ensure the new information is uploaded to the EAS.  
An Event Adjudication Site Manual will be provided to each site detailing which source documents 
are relevant and how these should be provided to the adjudication supplier. The anonymization and 
labelling requirements are also described in the site manual.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 39 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  40 of 88 
 
8.3.1 Time period and frequency for collecting AE and SAE information  
All events specified in Section 8.3 (for events related to pregnancy, see Appendix 4 , Section  10.4) 
must be collected and  reported. The events must be collected from the randomisation visit and until 
the end -of-trial visit, at the time points specified in the flowchart.  
Medical occurrences that take place or have onset prior to the time point from which AEs are 
collected wil l be recorded as concomitant illness/medical history. AE and SAE reporting timelines 
can be found in  Appendix [ADDRESS_1108986] has been 
discontinued from/completed the trial, and the investigator considers the event to be 
possibly/probably related to the trial product or r elated to trial participation, the investigator must 
promptly notify Novo Nordisk.  
8.3.2 Method of detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures for 
completing and transmitting SAE reports ar e provided in Appendix 3 , Section 10.3. 
Care should be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and non -
leading verbal questioning of the subject is the preferred method to inquire about events.  
8.3.3 Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts. All SAEs should be followed until final outcome of the event or the 
subject is lost to follow -up as describe d in Section 7.3. Further information on follow -up and final 
outcome of events is given in Appendix [ADDRESS_1108987]/ independent ethics committee ( IRB/IEC), and 
investigators. This also includes suspected unexpected serious adverse reacti ons (S[LOCATION_003]R).  
An investigator who receives an investigator safety report describing a SAE or other specific safety 
information (e.g. summary or listing of SAEs) from Novo Nordisk will review and then file it along 
with the investigator's brochure and will n otify the IRB/IEC, if appropriate according to local 
requirements.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 40 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108988]’s clinical signs and symptoms.  
Accidental overdose must be reported as a medication error. Intentional overdose must be re ported 
as misuse or abuse, please refer to Section 8.[ADDRESS_1108989] for overdose -related 
AE/SAE. A prolonged period of observation and treatment may be necessary, considering the  long 
half-life of semaglutide of approximately one week.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_18016].  
For more information on overdose, also consult the current version of the IB29 or any updates 
hereof.  
8.5 Pharmacokinetics  
 Blood samples for measuring plasma concentration of semaglut ide will be drawn at  
 visit 7 and visit 11 according to the flowchart (Section 1.2) 
 The dosing information should be transcribed into the CRF for the date and time of the last two 
doses (approx. -2 and -1 week) of trial product prior to the PK assessment.  
 The exact timing o f obtaining the PK sample must be recorded on the laboratory form.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 41 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  42 of 88 
 
 The purpose of measuring plasma semaglutide levels is to evaluate exposure -response 
relationship.  
 Blood samples for PK assessments must be collected, handled and shipped according to the  
 description in the laboratory manual supplied by [CONTACT_2237]. The bioanalysis of 
semaglutide PK will be performed by a special laboratory. Semaglutide PK samples will be 
stored at the special laboratory responsible for PK until final CTR in case N ovo Nordisk 
requests further analysis of the PK samples. Details of the bioanalysis will be outlined in a 
bioanalytical study plan issued by [CONTACT_93419].  
8.[ADDRESS_1108990] consented to 
participate in the optional biobank component of the trial. Refer to Section 8.8 and Appendix 6 , 
Section  10.6 for further details.  
8.8 Biomarkers  
Collection of samples for biomarker research is part of this trial. The following samples are required 
and will be collected from all subjects in this trial:  
 N-terminal pro -brain natriuretic peptide (NT -proBNP)  
 C-reactive protein (CRP)  
Collection of biosamples for future analysis (stored in a biobank) is a component  of this trial. 
Participation in the biobank component is optional. Subjects who do not wish to participate in the 
biobank component may still participate in the trial. For the biobank, samples will be collected 
according to Table  10-[ADDRESS_1108991] become available. The analyses may include biomarkers currently known or discovered 
in the future.  
Genetic analyses may include analysis of candidate genes or genetic markers throughout the 
genome w ith the purpose of understanding and predicting response to semaglutide as well as to 
understand  obesity, cardiovascular, metabolic, or related conditions.  
Analyses of circulating biomarkers will measure hormones, metabolites or other non -genetic serum 
entity with the purpose of understanding and predicting response to semaglutide as well as 
understanding obesity , cardiovascular, metabolic, or related conditions.  
The analyses are likely to be performed after the trial has come to an end, and results will th erefore 
not be part of the clinical trial report. The biobank samples may be stored at a central laboratory up 
to 15 years after the study has been reported.  
Refer to Appendix 6, Section 10.6. 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 42 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  43 of 88 
 
8.9 Immunogenicity assessments  
Not applicable for this trial.  
8.10 Health economics  
Not applicable for this trial.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 43 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  44 of 88 
 
9 Statistical considerations   
9.1 Statistical hypotheses  
The tests of superiority of semaglutide s.c. 2.4 mg once weekly versus placebo for the primary and 
confirmatory secondary endpoints are performed using a graphical testing  system (Figure  9-1) that 
preserve s the overall study -wise type I error of 5%.   
 
KCCQ -CSS: Kansas City Cardiomyopathy Questionnaire; CRP: C -Reactive Protein; 6MWD: six -minute  walking 
distance. Hierarchical comp osite  endpoint as defined in Section  [IP_ADDRESS]  
Figure  9-[ADDRESS_1108992], the multiple primary endpoints are tested, where for these two endpoints the alpha is split in 
1% for weight change and 4 % for change in KCCQ -CSS. The tests for the multiple endpoint will 
follow the weighted Holm -Bonferroni procedure57 (with weights one) such that if one of the two 
endpoints is superior then the full alpha can be recycled for the other endpoint and hence the 
remaining primary endpoint will be tested at the 5% significance level (two -sided).  
If both hypotheses are rejec ted and superiority is confirmed  for both primary endpoints , then  the 
confirmatory secondary endpoint will be tested according to  the flow and weights as specified  in 
Figure  9-1. The 5% alpha will be 50/50 split  between 6MWD and the hierarchical  composite 
endpoint , so that the hierarchical composite endpoint will be tested at  2.5% significance level , and i f 
superiority is confirmed , the 6MWD will be tested at 3.75% significance level. If superiority is not 
confirmed for th e hierarchical composite  endpoint, the 6MWD will be tested at 2.5% significance 
level. If superiority is confirmed for both 6MWD and the hierarchical composite endpo int, CRP will 
be tested at 5% significance level , but if  only 6MWD is confirmed CRP will be tested at 2.5% 
significance level, or if only the hierarchical composite is confirmed, CRP will be tested at 1.2 5% 
significance level.   
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 44 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1108993] 90% to detect differences on each of the dual 
primary endpoints  with a study -wise type I error rate of 5%. 
The calculations for the primary endpoints and confirmatory secondary endpoints 6MWD and CRP 
are based on a t test on the mean difference assuming equal variances in the arms . The calculations 
for the composite hierarchical secondary endpoint are based on the win ratio.   
In the NN9536 -4373 t rial (STEP -1) with 1961 randomised subjects  (BMI>= 27 kg/m2 at baseline)  
there was observed a treatment difference of 1 2% for change in BW between semaglutide  2.[ADDRESS_1108994] deviation across the groups were approximately 12  using the 
published 95% CIs  assuming KCCQ -OSS and KCCQ -CSS have similar variability . Furthermo re, 
using results from DEFINE -HF (a HFrEF population ) the standard deviati on for KCCQ -CSS was 
calculated to be 13.[ADDRESS_1108995] deviation 
of 70.  
Using data from NN9536 -4373 a mean ratio of 0.79 and 0.51 (semaglutide 2.4 mg versus placebo) 
was estimated for completer s (on treatment) at 20 and 68 weeks adjusted for baseline CRP. A 
coefficient of variation was estimated to be 1.23 using the residual variance on the log scale back  
transformed . We assume a mean ratio of 0.70 for completers between semaglutide 2.4 mg once 
weekly  versus placebo in this trial at 52 weeks.  
For the power calculations on the hierarchical compo site endpoint, it is assumed that 10 all-cause 
deaths (with a treatment effect corresponding to a hazard ratio of 0.9 ) and 15 subjects with heart 
failure h ospi[INVESTIGATOR_11956] (with a treatment effect corresponding to a hazard ratio of 0.8) will occur 
during the trial . A correlation of 0.5 between the KCCQ -CSS and 6MWD  is assumed  for this 
endpoint.  The power calculations for this endpoint are based on simulation of [ZIP_CODE] datasets.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 45 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  46 of 88 
 
In relation to treatment effects in non -completers using data from NN9536 -4373 we assume that 
25% of subjects discontinue permanently and 60% of these are retrieved at week 52. All subjects in 
the placebo arm are assumed to ha ve same effect as subjects who complete the trial on placebo. 
Retrieved subjects in the semaglutide s.c. 2.[ADDRESS_1108996] 
corresponding to half the treatment difference (compared to placebo) of subjects who complete the 
trial on semaglutide s.c. 2.[ADDRESS_1108997] corresponding to placebo. The attenuation of the 
assumed mean differences between treatment groups using these assumpti ons can be seen in 
Table  9-1. 
Table  9-1 Assumptions  and power for the confirmatory endpoints  given with an 
anticipated number of 516 randomised subjects  
Endpoint  Mean 
difference  
Completers  Mean  
Difference#  Standard 
deviation  Two -sided 
significance 
level (%)*  Marginal 
Power  
(%) 
Body weight  -12% -9.9%  8.5 1 >99.9%  
KCCQ -CSS 5.0 points  4.125 points  14  4 90% 
6MWD  30 metres  24.75 metres  70 2.5 96% 
Hierarchical 
composite  N/A N/A N/A 2.5 91% 
CRP   0.70 
Mean ratio  0.745  
Mean ratio  1.23 
CV 1.25 84% 
CRP is characterised by [CONTACT_803316]  (CV)  
#Assumed that 25% discontinue treatment with 60% retrieval with a halved treatment effect in retrieved subjects which 
corresponds to that 75% of subjects have a treatment effect as completers, 15% would have a halved treatment effect as 
completers and 10% would have no treatment effect.  *Minimum significance level it can be tested on.  
The sample size in this trial would essentially be governed by [CONTACT_803317] -CSS. Different scenarios can be observed in  
Table  9-2. 
Table  9-[ADDRESS_1108998] deviation with a significance level of 4% and a power of 
90%.  
Standard deviation   Mean difference  Sample size  
13 5 304 
14 5 352 
15 5 404 
13 4.125  446 
14 4.125  516 
15 4.125  592 
13 4 474 
14 4 548 
15 4 628 
 
  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 46 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  47 of 88 
 
9.3 Populations for analyses  
The following population s are defined : 
Population  Description  
Randomised  All subjects randomised  
Full analysis set (FAS)  All subjects randomised. Exclusion of data from analyses should be used 
restrictively, and normally no data should be excluded from the FAS. Subjects 
will be analysed according to the randomised treatment  
Safety  analysis set (SAS)  All subjects randomly assigned to trial treatment and who take at least [ADDRESS_1108999]:  
 In-trial: The in-trial period is defined as the uninterrupted time interval from date of 
randomisation to date of last contact [CONTACT_18018].  
 On-treatment (with trial product): A time -point is considered as ‘on -treatment’ if any dose 
of trial product has  been administered within the prior 2 weeks (14 days). The on -treatment 
period is defined as all times which are considered on -treatment.  
In general, the on -treatment period will therefore be from the date of first trial product 
administration to date of l ast trial product administration excluding potential off -treatment time 
intervals triggered by [CONTACT_18019].  
For the evaluation of AEs, the lag time for each on -treatment time interval is 5 weeks ( 35 days).  
The in -trial and on -treatment periods define the patient years of  observation (PYO) and patient 
years of exposure (PYE), respectively, as the total time duration in the periods . 
Effect endpoints will be analysed using the FAS; safety endpoints will be analysed using the SAS.  
9.4 Statistical analyses  
The statistical analysis plan (SAP) will be written, including a more technical and detailed 
elaboration of the statistical analyses. The SAP will be finali sed before breaking the blind to 
treatment assignment.  
9.4.[ADDRESS_1109000] with associated two -sided 
95% confidence intervals and p -values corresponding to two -sided tes ts of no difference.  
The last available and eligible observation at or before randomisation is used as  the baseline value.  
Data from all countries and sites will be analysed and reported together.  
9.4.2 Primary endpoints  
The primary endpoints are change in the KCCQ clinical summary score (points) and change in BW 
in percentage (BW -%) from baseline (week 0) to end  of treatment (week 52) as listed in Section 3. 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 47 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  48 of 88 
 
All tests are tests of superiority of semaglutide s.c. 2.4 mg once  weekly to placebo.  
Analyses addressing  the primary estimand  
The following statistical analyses and imputation methods are designed to address the primary 
estimand.  
The primary analysis model for change in the KCCQ -CSS (points) or change in BW (%) is a linear 
regression (ANCOVA) with randomised treatment , and with baseline KCCQ -CSS (points) and 
baseline BW (kg) , respectively,  as covariates.  The factor BMI subgroup ( BMI <35.0 kg/m2  versus  
BMI ≥35.0  kg/m2 ) is included in the model as it is used as a stratification variable in the 
randomisation scheme.  
The estimated treatment difference between semaglutide s.c. 2.4 mg once -weekly and placebo will 
be reported together with the associated two -sided 95% CI and corresponding p -value. All available 
data at week [ADDRESS_1109001] available observation during the on -treatment 
period (LAO -OT) of KCCQ -CSS or BW. Missing measurements for the prima ry endpoints at week 
52 for subjects on randomised treatment (at week 52) are imputed by [CONTACT_803318] 52 from subjects on randomised treatment in the relevant randomised 
treatment arms. Details of the imputation approach are  provided in the SAP  e.g. variables used in 
the imputation . 
Sensitivity analyses will address the primary estimand using a nonparametric method . 
9.4.3 Secondary endpoint(s)  
[IP_ADDRESS]  Confirmatory secondary endpoint  
The confirmatory secondary endpoint s are change in CRP and 6MW D (metres) from baseline 
(week  0) to end  of treatment (week 52) as well as the hierarchical composite endpoint as listed in 
Section 3. 
All tests are tests of superiority of semaglutide s.c. 2.[ADDRESS_1109002]  randomised to placebo  
within each stratum . For each of these pairs , a ‘treatment winner’ based on similar observation time 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 48 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  49 of 88 
 
will be declared based on the endpoint hierarchy. The win ratio (i .e. the proportion of winners 
randomised to  semaglutide s.c. 2.4 mg OW divided by [CONTACT_803319]) will be 
reported together with the associated two -sided 95% CI and corresponding p -value . Furthermore, 
the contribution of wins from each individual component of the hierarchical composite endpoint 
will be summarised .       
[IP_ADDRESS]  Supportive secondary endpoints  
For details on analyses of additional supportive secondary endpoints, please refer to the SAP.  
9.4.4 Exploratory endpoints  
For details on analyses of the exploratory endpoints, please refer to the SAP.  
[IP_ADDRESS]  Pharmacokinetic and/or pharmacodynamic modelling  
Exposure -response analyses will be use d as supportive evidence for the evaluation of efficacy and 
safety and further to support the investigated dose of semaglutide in subjects with HFpEF, obesity 
and T2D. Plasma semaglutide concentrations will be used to derive model -based estimates of 
steady -state average concentrations for each subject, utilizing a population pharmacokinetic 
modelling approach that leverages information from the STEP programme. Relevant efficacy and 
safety endpoints will be related to steady -state average concentrations and subjected to model -based 
exposure -response analysis. A modelling analysis plan will be prepared prior to database lock 
outlining details of the analyses. The results from the exposure -response analysis will be reported 
separately from the CTR.  
9.5 Interim anal yses  
No interim analyses are planned.  
9.6 Data monitoring committee  
There is no data monitoring committee for this trial  
9.7 Reporting of the main part of the trial  
Not applicable  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 49 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  50 of 88 
 
10 Supporting documentation and operational considerations  
10.1 Appendix 1: Regulatory, e thical, and trial oversight considerations  
10.1.1  Regulatory and ethical considerations  
 This trial will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki62 and applicable International Council for Harmonisation (ICH) 
Good Clinical Practice (GCP) Guideline63 
o Applicable laws and regulations  
 The protocol, informed consent form, investigator’s brochure (as applicable) and other relevant 
documents (e.g. advertisemen ts) must be submitted to an IRB/IEC and reviewed and approved 
by [CONTACT_1201]/IEC before the trial is initiated.  
 Regulatory authorities will receive the clinical trial application, protocol amendments, reports 
on SAEs, and the clinical trial report (CTR) accord ing to national requirements.  
 Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the trial design, except for changes necessary to eliminate an immediate safety 
hazard to trial subjects.  
 Before a site is a llowed to start screening subjects, written notification from Novo Nordisk must 
be received.  
 The investigator will be responsible for:  
o providing written summaries of the status of the trial annually or more frequently in 
accordance with the requirements, p olicies, and procedures established by [CONTACT_1201]/IEC 
and/or regulatory authorities  
o notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
o providing oversight of the conduct of the trial at the site and adherence to requirements 
of ICH guidelines, the IRB/IEC, and all other applicable local regulations  
o ensuring submission of the CTR synopsis to the IRB/IEC  
o reporting any potential serious breaches to the sponsor immediately after discovery  
10.1.2  Financial disclosure  
Inves tigators and sub -investigators will provide Novo Nordisk with sufficient, accurate financial 
information as requested to allow Novo Nordisk to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory autho rities. Investigators are 
responsible for providing information on financial interests during the course of the trial and one 
year after completion of the trial.  
For US sites: Verification under disclosures per Code of Federal Regulations (CFR) of Financial 
Conflict of Interest.  
10.1.3  Informed consent process  
 The investigator or his/her representative will explain the nature of the trial to the subject and 
answer all questions regarding the trial.  
 The investigator must ensure the subject ample time to com e to a decision whether or not to 
participate in the trial.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 50 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  51 of 88 
 
 Subjects must be informed that their participation is voluntary.  
 Subjects must be informed about their privacy rights.   
 Subjects will be required to sign and date a statement of informed consent that meets the 
requirements of local regulations, ICH guidelines63, Declaration of Helsinki62 and the 
IRB/IEC or site.  
 The medical record must include a statement that written informed consent was obtained before 
any trial related activity and the date when the written consent was ob tained. The authorised 
person obtaining the informed consent must also sign and date the informed consent form 
before any trial related activity.  
 The responsibility of seeking informed consent must remain with the investigator, but the 
investigator may del egate the task to a medically qualified person, in accordance with local 
requirements.  
 Subjects must be re -consented to the most current version of the informed consent form(s) 
during their participation in the trial.  
 A copy of the informed consent forms must be provided to the subject . 
10.1.[ADDRESS_1109003] may receive a “welcome to the trial  letter” and a “thank you for your participation letter” 
after completion of the trial. Further, the subject may receive other written information during the 
trial.  
All written information to subjects must be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].  
10.1.5   Data protection  
 Subjects will be assigned a [ADDRESS_1109004] are transferred to Novo Nordisk.  
 The subject and any biological material obtained from the subject will be identified by [CONTACT_41163], visit number and trial ID. Appropriate measu res such as encryption or leaving out 
certain identifiers will be enforced to protect the identity of subjects as required by [CONTACT_5737], 
regional and national requirements.  
 The subject must be informed about his/her privacy rights, including that his/her pers onal trial 
related data will be used by [CONTACT_18023]. The 
disclosure of the data must also be explained to the subject.  
 The subject must be informed that his/her medical records may be examined by [CONTACT_18024], by [CONTACT_6667]/IEC members, 
and by [CONTACT_6668].  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 51 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  52 of 88 
 
10.1.6  Committees structure  
[IP_ADDRESS]  Novo Nordisk safety committee  
Novo Nordisk will perform ongoing safety surveillance. If new safety sign als are identified, these 
will be evaluated by [CONTACT_18025]. The  safety committee may recommend 
unblinding of any data for further analysis, and in this case an internal trial independent ad hoc 
group will be established in order to maintai n the blinding of the trial personnel.  
[IP_ADDRESS]  Event adjudication committee  
An independent external EAC is established to perform ongoing blinded adjudication of selected 
AEs and deaths (see Table  8-1). 
The EAC will evaluate events sent for adjudication using pre -defined definitions and guidelines in 
accordance with the EAC charter. The evaluation is based on review of pre -defined clinical data 
collected by [CONTACT_30107]. The EAC is composed of permanent members covering all required medical 
specialities. EAC members must disclose any potential conflicts of interest and must be independent 
of Novo Nordisk. The EAC will have no authority to impact trial conduct, trial  protocol or 
amendments. The assessments made by [CONTACT_364069].   
[IP_ADDRESS]  Steering committee  
A steering committee will provide scientific and operational leadership for the trial . The committee 
will consist of experts from outside Novo Nordisk, and designated Novo Nordisk employees. The 
committee will operate under a charter agreed with Novo Nordisk.  
10.1.7  Dissemination of clinical trial data  
Information of the trial will be disclosed a t clinicaltrials.gov and novonordisk -trials.com. It will also 
be disclosed according to other applicable requirements, such as those of the International 
Committee of Medical Journal Editors (ICMJE)64, the Food and Drug Administration Amendment 
Act (FDAAA)65, European Commission Requirements1, 66, [ADDRESS_1109005] at 
these web sites, Novo Nordisk may disclose th e investigator’s contact [CONTACT_18026]. As a 
result of increasing requirements for transparency, some countries require public disclosure of 
investigator names and their affiliations.  
The primary completion date (PCD) is the last assessment of the  primary endpoint and is for this 
trial last subject first treatment (LSFT) + [ADDRESS_1109006] completed visit 
11. The PCD determines  the deadline for results disclosure at clinicaltrials.gov according to 
FDAAA.  
10.1.8  Data quality assurance  
[IP_ADDRESS]  Case report forms  
 Novo Nordisk or designee is responsible for the data management of this trial including quality 
checking of the data.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 52 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  53 of 88 
 
 All subject data r elating to the trial will be recorded on eCRFs unless transmitted electronically 
to Novo Nordisk or designee (e.g. laboratory and electronic PRO (ePRO)  data). The investigator 
is responsible for verifying that data entries are accurate and correct by [CONTACT_56857].  
 The following will be provided as paper CRFs:  
o Pregnancy forms  
 The following will be provided as paper CRFs to be used when access to the CRF is revoked or 
the CRF is temporarily unavailable:  
o AE forms  
o Safety information forms  
o Technical complaint forms (also to be used to report complaints on trial product not yet 
allocated to a subject)  
 Corrections to the CRF data may be made by [CONTACT_36322]’s delegated 
staff. An audit trail will be maintained in the CRF application containing as a minimum: the old 
and the new data, identification of the pers on entering the data, date and time of the entry and 
reason for the correction. If corrections are made by [CONTACT_093]’s delegated staff after the 
date when the investigator signed the CRF, the CRF must be signed and dated again by [CONTACT_1275].  
 The investigator must ensure that data is recorded in the CRF as soon as possible, preferably 
within 5 working days after the visit. Once data has been entered, it will be available to Novo 
Nordisk for data verification and validation purposes.   
[IP_ADDRESS]  Monitoring  
 The investigator must permit trial -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents (original documents, 
data and records). Direct access includes permission to examine, analys e, verify and 
reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the 
electronic medical record does not have a visible audit trail, the investigator must provide the 
monitor with signed and dated printouts. In addit ion, the relevant site staff should be 
available for discussions at monitoring visits and between monitoring visits (e.g. by 
[CONTACT_756]).  
 Trial monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_803320] s ite personnel are accurate, complete and verifiable from source 
documents; that the safety and rights of subjects are being protected, to monitor drug 
accountability and collect completed paper CRF pages, if applicable, and that the trial is 
being conducte d in accordance with the currently approved protocol and any other trial 
agreements, ICH GCP, and all applicable regulatory requirements.  
 Monitoring will be conducted using a risk -based approach including risk assessment, 
monitoring plans, centralised moni toring (remote assessment of data by [CONTACT_3454]) and 
visits to sites.  
 Monitors will review the subject’s medical records and other source data, to ensure consistency 
and/or identify omissions compared to the CRF.   
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 53 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  54 of 88 
 
[IP_ADDRESS]  Protocol compliance  
Deviations from the  protocol should be avoided. If deviations do occur, the investigator must 
inform the monitor without delay and the implications of the deviation must be reviewed and 
discussed.  
Deviations must be documented and explained in a protocol deviation by [CONTACT_803321], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the CRF or via listings from the trial database . 
10.1.9  Source documents  
 All data entered in the eCRF must be  verifiable in source documentation other than the CRF.  
 For e PRO s, data in the service providers’ database is considered source data.  
 Source documents provide evidence for the existence of the subject and substantiate the 
integrity of the data collected. Source documents are filed at the site.  
 Data reported on the paper CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents, or the discrepancies must be 
explained. The investigator may need to requ est previous medical records or transfer records. 
Also, current medical records must be available.  
 If source data is entered directly in a paper CRF, each data entry or clear series of data entries 
must be signed and dated separately by [CONTACT_803322].  
 It must be possible to verify subject’s medical history in source documents, such as subject’s 
medical record  
 The investigator must document any attempt to obtain external medical information by [CONTACT_41175](s) when information was reque sted, and who was contact[INVESTIGATOR_530].  
 Definition of what constitutes source data can be found in a source document agreement at each 
site. There will only be one source document defined at any time for any data element.  
10.1.10  Retention of clinical trial documentation  
 Records and documents, including signed informed consent forms, pertaining to the conduct of 
this trial must be retained by [CONTACT_1732] 15 years after end of trial unless local 
regulations or institutional policies require a longer retention perio d. No records may be 
destroyed during the retention period without the written approval of Novo Nordisk. No 
records may be transferred to another location or party without written notification to Novo 
Nordisk.  
 The investigator must be able to access his/h er trial documents without involving Novo Nordisk 
in any way. If applicable, eCRF and other subject data will be provided in an electronic 
readable format to the investigator before access is revoked to the systems and/or electronic 
devices supplied by [CONTACT_343842] o Nordisk. Site -specific CRFs and other subject data (in an 
electronic readable format or as paper copi[INVESTIGATOR_17951]) must be retained by [CONTACT_779]. A copy 
of all data will be stored by [CONTACT_3454].  
 Subject’s medical records must be kept for the maximum per iod permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 54 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109007] 
inform the subjects promptly and ensure appropriate therapy and follow -up. The investigator and/or 
Novo Nordisk must also promptly inform the regulatory authorities and IRBs/IECs and provide a 
detailed written explanation.  
Sites will be closed upon trial completion. A site is considered closed when all required documents 
and trial supplies have been collected and a site closure visit has been performed.  
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a site by [CONTACT_41177]:  
 failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, Novo Nordisk procedures or GCP guidelines  
 inadequate recruitment of subjects by [CONTACT_093]  
 discontinuation of further trial product development.  
10.1.[ADDRESS_1109008] of the trial at his/her site and must ensure adequate 
supervision of the conduct of the trial at the site. If any tasks are delegated, the investigator must 
maintain a log of appropriately qualified persons to whom he/she has delegated  specified trial -
related duties. The investigator must ensure that there is adequate and documented training for all 
staff participating in the conduct of the trial. It is the investigator’s responsibility to supervise the 
conduct of the trial and to prote ct the rights, safety, and well -being of the subjects.   
A qualified physician, who is an investigator or a sub investigator for the trial, must be responsible 
for all trial -related medical decisions.   
The investigator is responsible for filing essential do cuments (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data 
produced) in the investigator trial master file. The documents, including the subject identification 
code list must be  kept in a secure locked facility so that no unauthorized persons can get access to 
the data.   
The investigator will take all necessary technical and organisational safety measures to prevent 
accidental or wrongful destruction, loss or deterioration of dat a. The investigator will prevent any 
unauthorised access to data or any other processing of data against applicable law. This also 
includes ensuring that no indirect sharing of user credentials for IT systems used in this study takes 
place (e.g., by [CONTACT_803323] a way where user credentials have the 
possibility of being shared). The investigator must be able to provide the necessary information or 
otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have 
been taken.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 55 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109009] delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.  
If the investigator is n o longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk.   
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).  
10.1.[ADDRESS_1109010] liability for its products, and liability as assumed under the special 
laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.   
Novo Nordisk assumes no liability in the event of negligence or any other liability of the sites or 
investigators conducting the trial or by [CONTACT_18033].   
For country specific indemnity statements, please ref er to Appendix 7, Section 10.7. 
10.1.[ADDRESS_1109011], if deemed necessary by [CONTACT_3454]. 
Provided that certain conditions are fulfilled, Novo Nordisk may grant access to information 
obtained during  this trial to researchers who require access for research projects studying the same 
disease and/or trial product studied in this trial.  
Novo Nordisk may publish on its clinical trials website a redacted CTR for this trial.  
One investigator will be appoin ted by [CONTACT_18036] (signatory 
investigator) on behalf of all participating investigators.   
[IP_ADDRESS]  Communication of results  
Novo Nordisk commits to communicate and disclose results of trials regardless of outcome. 
Disclosure includes pu blication of a manuscript in a peer -reviewed scientific journal, abstract 
submission with a poster or oral presentation at a scientific meeting or disclosure by [CONTACT_11174].   
The results of this trial will be subject to public disclosure on external web si tes according to 
international and national regulations. Novo Nordisk reserves the right to defer the release of data 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 56 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 Septem ber 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  57 of 88 
 
until specified milestones are reached, for example when the CTR is available. This includes the 
right not to release the results of inter im analyses, because the release of such information may 
influence the results of the entire trial.  
At the end of the trial, one or more scientific publications may be prepared collaboratively by [CONTACT_1275](s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or 
communication for up to [ADDRESS_1109012] intellectual property.  
In all cases, the trial results will be reported in an objective, accurate, balanced and complete 
manner, with a discussion of the strengths and limi tations. In the event of any disagreement on the 
content of any publication, both the investigators’ and Novo Nordisk opi[INVESTIGATOR_17952].  
[IP_ADDRESS]  Authorship  
Novo Nordisk will work with one or more investigator(s) and other experts who have contributed to 
the trial concept or design, acquisition, analysis or interpretation of data to report the results in one 
or more publications.  
Authorship of publications should be in accordance with the Recommenda tions for the Conduct, 
Reporting, Editing and Publication of Scholarly Work in Medical Journals by [CONTACT_18037].68 
All authors will be provided with the relevant statistical tables, figures, and reports needed to 
evaluate the planned public ation.   
Where required by [CONTACT_18038], the investigator from each site will be named in an 
acknowledgement or in the supplementary material, as specified by [CONTACT_18038].   
[IP_ADDRESS]  Site-specific publication(s) by [CONTACT_1697](s)  
For a multicentre clinical trial, ana lyses based on single -site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. Thus, Novo Nordisk may deny a 
request or ask for deferment of the publication of individual site results until the primary manuscript 
is accepted for publication. In line with Good Publication Practice, such individual reports should 
not precede the primary manuscript and should alwa ys reference the primary manuscript of the trial.  
[IP_ADDRESS]  Investigator access to data and review of results  
As owner of the trial database, Novo Nordisk has the discretion to determine who will have access 
to the database.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 57 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  58 of 88 
 
10.2 Appendix 2: Clinical laboratory tests  
 The tests detailed in Table  10-1 will be performed by [CONTACT_803324] . 
 All laboratory results from visit 1 will be d isclosed to the investigators. For the remaining visits 
no laboratory results will be disclosed to the investigators.  
 Additional tests may be performed at any time during the trial as determined necessary by [CONTACT_41011] s. Only laboratory samples specified in the 
protocol should be sent to the central laboratory for analysis; if additional laboratory 
sampling is needed, e.g. to follow up on AEs, this must be done at a local laboratory.  
 The central lab will communicate to the investigator abnormal values of parameters not 
requested in the protocol but identified by [CONTACT_111428]/or their processes 
according to their lab SOPs. These data will not be transferred to the trial database. The 
investigator should re view such values for AEs and report these according to this protocol.  
 The investigator must review all disclosed laboratory results for concomitant illnesses and AEs.  
 Laboratory samples will be destroyed no later than at finalisation of the CTR except for  
samples collected for  the biobank for future use . 
Table  10-1 Protocol -required laboratory assessments  
Laboratory assessments  Parameters  
Glucose metabolism  
Visit: 1   HbA1c1 
Biomarkers  
Visit: 1, 7, 11  N-terminal pro -brain natriuretic peptide (NT -proBNP)  
 high sensitivity C -Reactive Protein (hsCRP)  
Pregnancy Testing  
Visit: 1, 2,  4, 5, 7, 8, 9, 10, 
11, 12  Urine human chorionic gonadotropin (hCG) pregnancy test (as needed for 
women of childbearing potential)2 
Biobank3 
Visit: 2, 7, 11  Whole blood (for genetic analysis)  (visit 2 only)  
 Serum (for analyses of circulating biomarkers)  
Pharmacokinetics  
Visit: 7, 11   Plasma semaglutide  
Notes:  
[ADDRESS_1109013] unless serum testing is required by [CONTACT_18039]/IEC.  
[ADDRESS_1109014] sign and date a separate informed consent form before samples are collected  
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 58 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  59 of 88 
 
10.3 Appendix 3: Adverse events: Definitions and procedures for recording, evaluation, 
follow -up, and reporting  
10.3.[ADDRESS_1109015] (IMP), whether or not considered related to 
the IMP.  
An AE can therefore be any unfavorable and unintended sign, including an abnormal laboratory 
finding, symptom or disease (new or exacerbated) temporally associated with the use of an IMP.  
 
Events meeting  the AE definition  
 Any abnormal laboratory test results or safety assessments considered clinically significant in 
the medical and scientific judgment of the investigator, including events that have worsened 
from prior to the time point from  which AEs are collected  
 Conditions detected or diagnosed after IMP administration even though it may have been 
present prior to the time point from which AEs are collected  
 Exacerbation/worsening of a chronic or intermittent condition including either an increase in 
frequency and/or intensity of the condition  
 Signs, symptoms or the clinical sequelae of a suspected drug -drug interaction  
 Signs, symptoms or the clinical sequelae of a suspected overdose of IMP regardless of intent  
 Obesity related surgical proc edures  
A "lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as 
an AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fulfil the definition.  
Events NOT  meeting the AE definition  
 Conditions present prior to the time point from which AEs are collected and anticipated day -
to-day fluctuations of these conditions, including those identified during screening or other 
trial procedures performed before exposure to IMP.  
Note: Conditions present or occurring prior to the time point from which AEs are collected 
should be recorded as concomitant illness/medical history.  
 Medical or surgical procedures (e.g. endoscopy, appendectomy). The condition that leads to 
the procedure is the AE. Exceptions include obesity related surgical procedures where the 
procedure (e.g. bariatric surgery) should be reported as the AE.  
 Medical or surgical p rocedures not preceded by [CONTACT_18040] a known condition.  
10.3.[ADDRESS_1109016] one of the following criteria:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_803287] e xisting hospi[INVESTIGATOR_11956]  
 Hospi[INVESTIGATOR_17953]/or treatment that would not have been appropriate in the physician’s 
office or outpatient setting. Complications that  occur during hospi[INVESTIGATOR_17954]. If a 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 59 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  60 of 88 
 
complication prolongs hospi[INVESTIGATOR_17955], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_11956]” occurred or was necessary, the AE 
should be considered serious.  
 Hospi[INVESTIGATOR_17956] (e.g. elective medical or surgical procedures) of a 
condition that was present prior to the time point from which AEs are collected, and that did 
not worsen, is not considered an AE.  
Note:  
 Hospi[INVESTIGATOR_803288], trial related, social and convenience reasons do not 
constitute AEs and should therefore not be reported as AEs or SAEs.   
 Hospi[INVESTIGATOR_111371], planned before trial inclusion, are not 
considered AEs or SAEs.   
d. Results in persistent or significant disability/incapacity  
 The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
 This definition is not intended to include experience of relatively minor medical signif icance, 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g. sprained ankle), which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.  
e. Is a congenital anom aly/birth defect  
f. Important medical event:  
 Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations. This includes important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_803289]. These events should usually be considered serious and reported 
as SAEs us ing the important medical event criterion.  
 The following AEs must always be reported as SAEs using the important medical event 
criterion if no other seriousness criteria are applicable:  
 Suspi[INVESTIGATOR_17960]  
 Risk of liver injury defined as alanine aminotransferase (ALT) or aspartate aminotransferase 
(AST) >3 x upper normal limit ( UNL ) and total bilirubin >2 x UNL where no alternative 
aetiology exists (Hy's law)  
 
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 60 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  61 of 88 
 
10.3.3  Description of events for adjudication and AEs  requiring additional data collection  
Description of events for adjudication and AEs requiring additional data collection (on 
specific event form)  
Events for adjudication  
An event for adjudication is a selected AE or death evaluated by [CONTACT_111420] 
a blinded manner, please refer to Section [IP_ADDRESS]  and Figure  10-1. 
 Death: 
All cause death  
 Heart failure hospi[INVESTIGATOR_803285]:  
New epi[INVESTIGATOR_111374], unscheduled hospi[INVESTIGATOR_803290]/office/emergency department visit  
Adverse events requiring additional data collection  
Acute Pancreatitis  
Diagnosis of acute p ancreatitis requires two of the following three features:  
1. abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, 
epi[INVESTIGATOR_36236])  
2. serum lipase activity (and/or amylase activity) at least three ti mes greater than the upper limit 
of normal  
3. characteristic findings of acute pancreatitis on imaging.  
Medication error  
A medication error is an unintended failure in the IMP treatment process that leads to, or has the 
potential to lead to, harm to the subject, such as:   
 administration of wrong drug  
Note: Use of wrong dispensing unit number (DUN) is not considered a medication error 
unless it results in administration of wrong drug.  
 wrong route of administration, such as intramuscular instead of subcutaneous  
 accidental administration of higher dose than intended. The administered dose must deviate 
from the intended dose to an extent where clinical consequences for the trial subject w ere 
likely to happen as judged by [CONTACT_093], although they did not necessarily occur.  
Note: missed doses or drug pauses are not to be reported as a medication error.  
Misuse and abuse   
 Situations where the IMP is intentionally and inappropriately use d not in accordance with the 
protocol (e.g. overdose to maximise effect)  
 Persistent or sporadic, intentional excessive use of an IMP which is accompanied by [CONTACT_18041] (e.g. overdose with the intention to cause harm)  
Medicati on error, misuse and abuse must always be reported as an AE (e.g. accidental overdose, 
intentional overdose or other) on a separate AE form, and a medication error, misuse and abuse 
form must be completed. In case of a medication error and/or misuse and ab use resulting in a 
clinical consequence (e.g. gastroin testinal adverse events  or other), this must be reported on an 
additional AE form.  
 
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 61 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  62 of 88 
 
10.3.4  Recording and follow -up of AE and/or SAE  
AE and SAE recording  
 SAEs and  AEs listed in Section 8.3 and AEs/SAEs in connection with pregnancies, must be 
recorded by [CONTACT_18042]. The investigator will attempt to establish a diagnosis 
of the event based on signs, symptoms, and/ or other clinical information. In such cases, the 
diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.  
 When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospi[INVESTIGATOR_1088],  laboratory and diagnostics reports) related to the 
event.  
 There may be instances when copi[INVESTIGATOR_14168] (e.g. medical records) for certain 
cases are requested by [CONTACT_3454]. In such cases, all subject identifiers, except for the 
subject number,  will be redacted on the copi[INVESTIGATOR_803291].  
 For all non -serious AEs, the applicable forms should be signed when the event is resolved or 
at the end of the trial at the latest. For sign -off of SAE related forms , refer to “AE and SAE 
reporting via paper CRF” later in this section.  
 Novo Nordisk products used as concomitant medication: if an AE is considered to have a 
causal relationship with a Novo Nordisk marketed product used as concomitant medication in 
the tri al, it is important that the suspected relationship is reported to Novo Nordisk, e.g. in the 
alternative aetiology section on the safety information form. Novo Nordisk may need to 
report this AE to relevant regulatory authorities.  
 
Assessment of severity  
The investigator will assess severity for each event reported during the trial and assign it to one of 
the following categories:   
 Mild:  An event that is easily tolerated by [CONTACT_423], causing minimal discomfort and not 
interfering with everyday activiti es. 
 Moderate:  An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
 Severe:  An event that prevents normal everyday activities.   
Note: An AE that is assessed as severe should not be confused with a SAE. Both AEs and SAEs 
can be assessed as severe.  
 
Assessment of causality  
 The investigator is obligated to assess the relationship between IMP and the occurrence of 
each AE/SAE.  
 Relationship between an AE/SAE and the relevant IMP should be assessed as:  
 Probable - Good reason and sufficient documentation to assume a causal relationship.  
 Possible - A causal relationship is conceivable and cannot be dismissed.  
 Unlikely - The event is most likely related to aetiology other than the IMP.  
 Alternative aetiology, s uch as underlying disease(s), concomitant medication, and other risk 
factors, as well as the temporal relationship of the event to IMP administration, will be 
considered and investigated.  
 The investigator should use the investigator’s brochure for the asse ssment. For each AE/SAE, 
the investigator must document in the medical records that he/she has reviewed the AE/SAE 
and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred, and the investigator has minimal 
informati on to include in the initial report. However, it is important that the investigator 
always assesses causality for every event before the initial transmission of the SAE data.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 62 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  63 of 88 
 
 The investigator may change his/her opi[INVESTIGATOR_17963], in light of follow -up information, 
and update the causality assessment in the CRF.  
 The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Final outcome  
The investigator will select the most appropriate outcome:  
 Recovered/resolved : The subject has fully recovered, or by [CONTACT_18043]  
 Recovering/resolving : The condition is improving, and the subject is expected to recover 
from th e event. This term may be applicable in cases of chronic conditions, cancer or AEs 
ongoing at time of death (where death is due to another AE).  
Note: For SAEs, this term is only applicable if the subject has completed the follow -up period 
and is expected to recover.  
 Recovered/resolved with sequelae : The subject has recovered from the condition but with 
lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE 
criterion, the AE must be reported as an SAE.  
 Not recovered/not r esolved : The condition of the subject has not improved, and the 
symptoms are unchanged, or the outcome is not known.  
Note: This term may be applicable in cases of chronic conditions, cancer or AEs ongoing at 
time of death (where death is due to another AE ).  
 Fatal : This term is only applicable if the subject died from a condition related to the reported 
AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as 
“recovered/resolved”, “recovering/resolving”, “recovered/resolved with sequelae” or “not 
recovered/not resolved”. An AE with a fatal outcome must be reported as an SAE.  
 Unknown : This term is only applicable if the subject is lost to follow -up. 
 
Follow -up of AE and SAE  
The investigator is obligated to perform or arrange  for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_18044]/or causality of the AE or SAE as fully as possible (e.g. severe hypersensitivity reactions). 
This may includ e additional laboratory tests (e.g. skin prick test) or investigations, 
histopathological examinations, or consultation with other health care professionals.  
If a subject die during participation in the trial or during a recognised  follow -up period, the 
investigator should provide Novo Nordisk with a copy of autopsy report including 
histopathology.  
New or updated information will be recorded in the CRF.  
10.3.5  Reporting of SAEs  
SAE reporting via electronic CRF  
 Relevant forms (AE and safe ty information form) must be completed in the eCRF.  
 For reporting and sign -off timelines, see Figure  10-1 below.  
 If the eCRF is unavailable for more than 24 hours, then the site will use the paper AE form, 
and if the eCRF is unavailable for more than 5 calendar days, then the site will use the safety 
information form (see box below).  
 The site will enter the SAE data into the eCRF as soon as it becomes available.  
 After the trial is completed, the trial database will be locked, and the e eCRF will be 
decommissioned to prevent the entry of new data or changes to existing data. If a site receives 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 63 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109017] or receives updated data on a previously reported SAE 
after eCRF decommission, then the site can report this information on a paper AE and safety 
information form (see box  below) or to Novo Nordisk by [CONTACT_756].  
 
AE and SAE reporting via paper CRF  
 Relevant CRF forms (AE and safety information form) must be forwarded to Novo Nordisk 
in accordance with Section 10.1.5 . 
 For SAEs, initial notification via telephone is acceptable, although it does not replace the 
need f or the investigator to complete the AE and safety information form within the 
designated reporting timelines (as illustrated in the figure below):  
 AE form within 24 hours  
 Safety information form within 5 calendar days  
 Both forms must be signed within [ADDRESS_1109018] knowledge by [CONTACT_093].  
 The specific event form for AEs requiring additional data collection within [ADDRESS_1109019] details for SAE reporting can be found in the investigator trial master file.  
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 64 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  65 of 88 
 
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information  
Definitions  
Woman of childbearing potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile.   
If fertility is unclear (e.g. amenorrhea in adolescents or athletes), and a menstrual cycle cannot be 
confirme d before first dose of trial treatment, additional evaluation should be considered.  
Females in the following categories are not considered WOCBP  
1. Premenarcheal  
2. Females with one or more of the following:  
Documented total hysterectomy  
Documented bilateral sal pi[INVESTIGATOR_803292] (e.g. 
Müllerian agenesis, androgen insensitivity), investigator discretion should be applied in determining 
trial enrolme nt. 
3. Postmenopausal female:  
 A postmenopausal state is defined as amenorrhoea for 12 months without an alternative medical 
cause.  
 Females ≥ 50 years of age can be considered postmenopausal (irrespective of treatment with a 
hormonal contraception or hormone replacement therapy (HRT)) if they have both:  
 Amenorrhoea and  
 Documentation of 2 high follicle stimulating hormone (FSH) measurements in the 
postmenopausal range and one of these was observed ≥1 year prior to screening.  
 Females ≥ 60 years of age can be considered postmenopausal.  
Females on HRT and whose menopausal status is in doubt are considered of childbearing potential 
and will be required to use one of the highly effective contraception methods.  
Note: Documentation regarding categories 1 -3 can come  from the site staff’s review of subject’s 
medical records, medical examination or medical history interview.  
Contraception guidance  
Male subjects   
No contraception measures are required for male subjects as the risk of teratogenicity/fetotoxicity 
caused b y transfer of semaglutide in seminal fluid is unlikely.  
Female subjects  
Female subjects of childbearing potential are eligible to participate if they agree to use methods of 
contraception consistently and correctly as described in table(s) below:
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 65 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  66 of 88 
 
Table  10-2 Highly effective  contraceptive methods  
CONTRACEPTIVESa ALLOWED DURING THE TRIAL INCLUDE:  
Highly effective methodsb,d that have low user dependency  (Failure rate of <1% per year when 
used consistently and correctly):  
 Implantable progestogen -only hormone contraception associated with inhibition of ovulationb  
 Intrauterine device (IUD)  
 Intrauterine hormone -releasing system (IUS)b  
 Bilateral tubal occlusi on 
 Vasectomized partner  
Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole 
sexual partner of the woman of childbearing potential, and the absence of sperm has been confirmed. If 
not, an additional highly e ffective method of contraception should be used. Spermatogenesis cycle is 
approximately 90 days.  
Highly effective methodsb, d that are user dependent  (Failure rate of <1% per year when used 
consistently and correctly):  
 Combined (estrogen - and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc 
o oral 
o intravaginal  
o transdermal  
o injectable  
 Oral/injectable progestogen -only hormonal contraception associated with inhibition of 
ovulation  
 Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the trial treatment. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of  the trial and the 
preferred and usual lifestyle of the subject.  
NOTES  
a) Contraceptive use by [CONTACT_18046].  
b) Failure rate of <1%  per year when used consistently and correctly. Typi[INVESTIGATOR_172041].  
c) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.  
d) Contraception should be utilised  during the treatment period and for at least 35 days (corresponding to 
time needed to eliminate trial product) after the last dose of trial product.   
Pregnancy testing  
 Additional pregnancy testing should be performed during the treatment period, if required 
locally (Appendix 7, Section  10.7). 
 Women/WOCBP should only be included after a negative highly sensitive urine or serum 
pregnancy test (refer to Appendix 2 , Section  10.2). 
 A pregnancy test should be performed at the end of relevant systemic exposure (refer to 
Appendix 2 , Section  10.2). 
 Pregnancy testing should be performed whenever a menstruation is missed or when pregnancy 
is otherwise suspected.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 66 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  67 of 88 
 
 
Collection of pregnancy information   
Female subjects who become pregnant   
 Investigator will collect pregnancy information on any female subject who becomes pregnant 
while participating in this trial.  
 Information will be recorded on the appropriate form and submitted to Novo Nordisk within [ADDRESS_1109020]'s pregnancy  (see Figure  10-2). 
 Subject will be followed to determine the outcome of the pregnancy. The investigator will 
collect follow -up information on subject and neonate which will be forwarded to Novo Nordisk 
within 14 calendar days. Generally, follow -up will not be required for longer than 1 month 
beyond the delivery date.  
 Any termination of pregnancy will be reported, regardl ess of foetal status (presence or absence 
of anomalies) or indication for procedure.  
 While pregnancy itself is not considered to be an AE or SAE, any AE in connection with 
pregnancy or elective termination of a pregnancy for medical reasons will be reporte d as an AE 
or SAE. If relevant, consider adding ‘gestational’, ‘pregnancy related’ or a similar term when 
reporting the AE/SAE.  
 Pregnancy outcome should be documented in the subject's medical record. Abnormal pregnancy 
outcome (e.g. spontaneous abortion, f oetal death, stillbirth, congenital anomalies and ectopic 
pregnancy) is considered an SAE.  
 Any SAE occurring as a result of a post -trial pregnancy which is considered possibly/probably 
related to the IMP by [CONTACT_803325] 
10.3. While the investigator is not obligated to actively seek this information in former subjects, 
he or she may learn of an SAE through spontaneous reporting.  
Maternal form 1b  
  14 calendar days after birthMaternal form 1a
  14 calendar daysAfter birth/
termination 
of pregnancy
No additional 
action Normal outcome Maternal form 2   14 calendar days
Paternal form*1   14 calendar days Abnormal outcome 
Pregnancy 
verified
*1 Further information collected on Paternal form for male partners of 
female subjects requires signing of specific informed consent.
AE/SAEs in connection with the pregnancy and in the foetus/newborn 
should follow the timelines in Figure 10.1.Prior to 
birth or 
pregnancy 
termination For female subjects
 
Figure  10-[ADDRESS_1109021] who becomes pregnant while participating in the trial will discontinue IMP.   
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 67 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  68 of 88 
 
10.5 Appendix 5: Technical complaints: Definition and procedures for recording, 
evaluation, follow -up and reporting  
10.5.1  Definition of technical complaint  
Technical complaint definition  
 A technical complaint is any written, electronic or oral communication that alleges product 
(medicine or device) defects. The technical complaint may be associated with an AE but does 
not concern the AE itself.  
Examples of technical complaints:  
 Problems with the physical or chemical appearance of trial products (e.g. discoloration, particles 
or contamination)  
 Problems with packaging material including labelling  
 Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen -injector and the needle)  
Time period for detecting technical complaints  
All technical complaints  which occur from the time of receipt of the product at site until the time 
of the last usage of the product must be collected for products predefined on the technical 
complaint form.  
10.5.[ADDRESS_1109022] be reported on a separate technical c omplaint form:  
1. One technical complaint form must be completed for each affected DUN.  
2. If DUN is not available, a technical complaint form for each batch, code or lot number must 
be completed.  
 
Timelines for reporting of technical complaints to Novo Nordisk  
The investigator must complete the technical complaint form in the CRF within:  
 24 hours if related to an SAE  
 [ADDRESS_1109023] enter the information on the technical complaint 
form in the CRF.  
 
Follow -up of technical complaints  
The investigator is responsible for ensuring that new or updated information will be recorded on 
the originally completed form.  
 
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 68 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109024].  
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 69 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  70 of 88 
 
10.6 Appendix 6: Retention of human biosamples and genetics  
In countries where applicable, the trial will involve collection of human biosamples to be stored in a 
central archive for future use. Subjects must sign and date a separate informed consent form before 
biosamples are collected.  
The following samples will be collected and stored:  
 Whole blood (for genetic analysis) – at baseline (visit 2)  
 Serum (for analysis of circulating biomarkers) – at baseline (visit 2), week 20 (visit 7), and end 
of treatment (visit 1 1). 
As new biomarkers related to the disease and/or safety, efficacy or mechanism of action of 
semaglutide may evolve during the conduct of the trial, the analyses of the stored biosamples may 
also include biomarkers that are unknown at present or have not been included in the scientific 
hypotheses at initi ation of the trial.  
The biosamples will be stored at a central storage facility contracted by [CONTACT_3454]. Only Novo 
Nordisk and storage facility employees will be able to access the stored biosamples. The biosamples 
may be transferred to other countries  for analysis and will be destroyed at the latest 15 years after 
the trial has been reported.  
Patients may withdraw from the biobank component of the trial at any time, independent of 
participation in the trial. The patient can cho ose to do so at any given  time while in the trial or after 
the end of the trial. If a patient withdraws from the biobank component all stored biosamples 
obtained from their own body will be destroyed.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 70 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  71 of 88 
 
10.7 Appendix 7: Country -specific requirements  
Argentina:  
 Section 5.2, exclusion criteria #18 and Appendix 4 (Section  10.4): Contraceptive methods and 
pregnancy tests will be reimbursed by [CONTACT_456]. Monthly testing with highly sensitive 
urine pregnancy tests is required for woman of childbearing potential (WOCB P). 
 Section 6.7: In reference to treatment after end of trial: the sponsor commits to comply with 
what is stated in point 6.8 of the current local reg ulation, disposition 6677/10. According to 
it, commits to comply with the following: “For Argentina, after the conclusion of subject´s 
participation in the study, trial doctor will discuss with subjects the best alternatives for 
future treatment. If trial doctor, based on his/her adequately justified medical analysis, 
decides that the Sponsor’s study drug is the best available treatment option for the subject, 
trial doctor will prescribe the study drug, which must be approved by [CONTACT_20601]. 
The Sp onsor (Novo Nordisk Pharma Argentina S.A.) will provide access to the Sponsor’s 
study drug to the subject for the time the Ethics Committee decides or until access is ensured 
by [CONTACT_803326].  Subjects 
must visit trial doctor to receive the Sponsor’s study drug and will have to provide 
information about health status and any possible side effects that may have been experienced 
since last visit.  
 
Australia:  
 Comply with Medicines Australia Guide lines for Compensation for Injury Resulting from 
Participation in a Company Sponsored Clinical Trial, version 160104 16 January 2004.  
 
Czech Republic:  
 Section 5.2, exclusion criteria #18 and Appendix 4  (Section  10.4): A monthly pregnancy test 
(urine) is required for all women of childbearing potential.  
 Appendix 2  (Section  10.2), laboratory assessments: In addition to the parameters listed in 
Appendix 2, amylase and lipase will be analysed.  
 Section 8.3 and Appendix 3  (Section  10.3): All AEs, irrespective of seriousness, should be 
collected from the day of randomisation and until the follow -up visit/end of trial visit, at the 
time points specified in the flowchart.   
 
Denmark:   
 Section 5.2, exclusion criteria #18 and Appendix 4  (Section  10.4): Contraceptive requirements 
as per EU CTFG guideline: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf  
 
[LOCATION_013]  
 Subject’s full Date of Birth is not allowed to be collected and must be shortened to year of birth  
 Section 1.2 Flowchart, section 5.2, exclusion criteria #18, Appendix 2  (Section  10.2) and 
Appendix 4  (Section  10.4): A monthly pregnancy test (urine) is required for all women of 
childbearing potential.  
 Section 8.3 and Appendix 3 (Section  10.3): All AEs, irrespective of seriousness, should be 
collected from the day of randomisation and until the follow -up visit/end of trial visit, at the 
time points specified in the flowchart.   
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 71 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  72 of 88 
 
 
Israel:  
 Section 8.7, 8.8 and Appendix 6  (Section  10.6): No subjects from Israel will participate in the 
option al biobank part of the trial, and no genetic testing will be performed as noted in 
sections 8.7 and 8.8. 
 
Poland:  
 Section 5.2, exclusion criteria #18 and Appendix 4  (Section  10.4): Contraceptive measures 
considered adequate include highly effective contraceptive methods in accordance with the 
Clinical Trial Facilitation Group: Recommendations related to contraception and pregnancy 
testing in clinical trials.  
 Novo Nordisk carries l iability for the Trial exclusively in the scope defined by [CONTACT_803327] 6 September 2001 
(uniform version Journal of Laws of 2008 No. 45 item 271 with amendments). In order to 
supp ort potential claims for liability attributable to the Trial, Novo Nordisk and Investigator 
are covered by [CONTACT_136779].  
 
Spain:  
 Appendix 1  (Section  10.1): Retention of clinical trial documentation is 25 years according to 
the new Spanish Royal Decree 1090/2015  
 Section 5.2, exclusion criteria #18 and Appendix 4  (Section  10.4): Contraceptive measures 
considered adequate include highly effective contraceptive methods in accordance with the 
Clinical Trial Facilitation Group: Recommendations related to contraception a nd pregnancy 
testing in clinical trials.   
 
[LOCATION_008]:  
 Section 5.2, exclusion criteria #18 and Appendix 4  (Section  10.4): Contraceptive measures 
considered adequate include highly effective contraceptive methods in accordance with the 
Clinical Trial Facilitation Group: Recommendations related to contraception and pregnancy 
testing in clinical trials.  
 Section 1.2 Flowchart, section 5.2, exclusion criteria #18, Appendix 2  (Section  10.2) and 
Appendix 4  (Section  10.4): A monthly pregnancy test (urine) is required for all women of 
childbearing potential.   
  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 72 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  73 of 88 
 
10.8 Appendix 8: Mitigations to ensure patient safety and data inte grity during an 
emergency situation  
Definition and scope of appendix  
In case local restrictions, e.g. due to a COVID -[ADDRESS_1109025] Novo Nordisk to allow for implementation of mitigations mentioned in this appendix 
based on mutual agreement.  
Table  10-3 indicates the minimum requirements for assessments that should be performed during a 
lock-down, but sites should always try to follow the asse ssments outlined in Section 1.2 (original 
flowchart) to the extent possible. Implementation of specific mitigations should be based on 
assessment of feasibility at the individual site.  
Sites should comply with local regulations, requirements and/or guidelines.  
Visits  
Screening (Visit 1) and randomisation/baseline (Visit 2) should always be performed as physical 
on-site visits. If a site is unable to pe rform these visits on -site, screening and randomisation of new 
participants at that site should be on hold until on -site visits are possible. Participants that cannot 
attend on -site visits [ADDRESS_1109026] possible. If not, 
assessments can be conducted remotely using telemedicine or as home visits. The visit window for 
visit 11 can be extended for up to 4 weeks. If the assessments at visit 7 cannot be performed on -site, 
using telemedicine or home visits, the visit window can be extended for up to 8 weeks.  
Other on -site visits (Visits 3, 4, 5, 6, 8, 9 and 10) can be converted to telemedicine (video, phone or 
similar) or home visits.  
At each visit the investigator must  indicate in the eCRF how the visit was performed and specify the 
reason for the preferred assessment method.  
Assessments  
Local laboratories or diagnostic facilities can be used at the investigator’s discretion if on -site visits 
are not possible or in case  of temporary lockdown of the central laboratory. Only findings meeting 
the definition for an AE  should be reported in the eCRF, refer to Section 10.1.[ADDRESS_1109027] possible time 
point following the originally sc heduled visit.  
Assessments used for the primary and secondary endpoints at Visits 7 and 11 (weight, outcome 
assessments and lab samples) should be prioritised. In addition, all participants must have ECG 
performed at Visit [ADDRESS_1109028] has 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 73 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109029] to sign a separate 
informed consent form.  
Study intervention  
Alternative dispensing methods may be i mplemented, and details will be communicated and 
documented. The dispensing options will be provided by [CONTACT_3454] A/S and will be based on 
options and requirements at country level and if permitted by [CONTACT_427].  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 74 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  75 of 88 
 
Table  10-3 Minimum assessments following randomisation to be performed during lockdown  
Please refer to Section 1.2 for the full  flowchart.  
Procedures marked with a black X should be prioritised. If deemed necessary because of the lockdown, Visits 3, 4, 5, 6, 8, 9 and 10 can be fully converted to 
phone visits and procedures marked with a red X will subsequently be cancelled.  
 Scre ening  Randomisation  Maintenance period  End of 
treatment  End of trial  
Visit/Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +7  
Informed consent and demographya (10.1.3 ) X            
Inclusion and exclusion criteria ( 5.1, 5.2) X X           
Physical examination ( 8.2.1 ) X X         X  
Medical history/Concomitant illness ( 8.2.1 ), Tobacco useb   X           
Childbearing potential ( 10.2, 10.4) X            
Concomitant medication ( 6.5)  Xc X X X X Xc X Xc X Xc X 
Body weight ( 8.1.1 ) X X X X X X X X X X X  
Height / BMI ( 8.1.1 ) X            
Waist circumference ( 8.1.1 )  X     X    X  
Patient Global Impression of Status (PGI -S) for KCCQ ( 8.1.2 ) X X     X  X  X  
Patient Global Impression of Change (PGI -C) for KCCQ ( 8.1.2 )  X     X  X  X  
Kansas City Cardiomyopathy Questionnaire (KCCQ) ( 8.1.2 ) X X     X  X  X  
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 75  of 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  76 of 88 
 
 Scre ening  Randomisation  Maintenance period  End of 
treatment  End of trial  
Visit/Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +7  
European Quality of Life five Dimensions five Level (EQ -5D-5L) ( 8.1.2 )  X     X    X  
Patient Global Impression of Status (PGI -S) for 6MWT ( 8.1.2 ) X X     X    X  
Patient Global Impression of Change (PGI -C) for 6MWT ( 8.1.2 )  X     X    X  
Six-minute walk test (6MWT) ( 8.1.2 ) X X     X    X  
NYHA classification / Vital Signs ( 8.2.2 , 8.2.4 )  X      X    X  
Electrocardiogram (ECG) ( 8.2.3 ) X          X  
Echocardiography ( 8.1.3 ) X Xd         Xd  
Laboratory assessments ( 10.2) X X     X    X  
Semaglutide plasma concentration ( 10.2)       X    X  
Pregnancy test (only for women of childbearing potential)e (10.2) X X  X X  X X X X X X 
Healthy lifestyle counselling ( 5.3)  X X X X X X X X X X  
Adverse event and Events for adjudication ( 8.3, 10.3)   X X X X X X X X X X 
Medication error, Misuse and Abuse ( 8.3, 10.3.3 )  X X X X X X X X X X  
Drug dispensing ( 6)  
X X X X X X X X X   
Training in trial product, pen -handling ( 6.1)  X X X X    X    
Hand Out Directions for Use ( 6.1)  X           
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 76  of 88
CONFIDENTIAL
Protocol        Date:  09 September 2022  Status:  Final  Novo Nordisk  
Trial ID: EX9536 -4665        Version:  6.0 Page:  77 of 88 
 
 Scre ening  Randomisation  Maintenance period  End of 
treatment  End of trial  
Visit/Phone  V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 P12 
Timing of Visit (Weeks)  Up to - 2 0 4 8 12 16 20 28 36 44 52 57 
Visit Window (Days)  0 to +13  0 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 0 to +[ADDRESS_1109030]  X            
Drug Accountability ( 6.2)  X X X X X X X X X X  
IWRS session  X X X X X X X X X X X  
a) Demography consists of date of birth, sex, race and ethnicity (according to local regulation – [LOCATION_013]: for country -specific requirements, please see Appendix 7 (Section 10.7)). 
b) Tobacco use is defined as smoking at least one cigarette or equivalent daily.  
c) Dose to be collected for loop diuretics.  
d) Only relevant for subjects included in the echocardiographic sub -study.  
e) For women of childbearing potential only. In addition to the planned assessments, urine dipstick pregnancy test should be per formed at any time during the trial if a menstrual period is 
missed, or if pregnancy is suspected. (according to local regulation – [LOCATION_008] and [LOCATION_013]: for country -specific requirements, please see Appendix 7 (Section 10.7)). 
 
 
 
 
 
EX9536-4665 EX9536 0  |  . -  | 1 VV-TMF-5539529
  Protocol  4665 V6  | 77  of 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  78 of 88 
 
10.9 Appendix 9: Abbreviations  
6MWT  six-minute walk test   
6MWD  six-minute walking distance  
AE adverse event  
BMI  body mass index  
BNP  brain natriuretic peptide  
BW body weight  
CI confidence interval  
COVID -[ADDRESS_1109031]  
GCP  Good Clinical Practice  
GLP -1 glucose like peptide -1 
HbA1 c haemoglobin A1 c 
HF heart failure  
HFpEF  heart failure with preserved ejection fraction  
HFrEF  heart failure with reduced ejection fraction  
HRT  hormone replacement therapy  
hsCRP  high sensitivity  C-Reactive Protein  
IB Investigator’s Brochure  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IMP investigational medicinal product  
IRB institutional review board  
IV intravenous  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 78 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109032]  
SAE  serious adverse event  
SAP statistical analysis plan  
SAS safety  analysis set  
s.c. subcutaneous  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
T2D type 2 diabetes  
TMM  trial materials manual  
UNL  upper normal limit  
VAS  visual analogue scale  
WOCBP  woman of child bearing potential  
 
 
 
 
 
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 79 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  80 of 88 
 
10.10  Appendix 10: Protocol amendment history  
The protocol amendment summary of changes table for the current updated protocol is located 
directly before the Table of Contents.  
Protocol version 5.0 (12 February 2021)  
This amendment is considered to be non -substantial based o n the criteria set forth in Article 10(a) of  
Directive 2001/20/EC of the European Parliament and the Council of the European Union1 because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
 
Overall rationale for preparing protocol, version 5 .0: 
The overall rationale for the change implemented in the amended protocol is to address comments  
received from the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).  
 
Section # and 
name  [CONTACT_18054]  10.7: 
Appendix 7  
Country -specific  
Requirements 
[LOCATION_013]  All AEs, irrespective of seriousness, should be 
collected from the day of randomisation and until 
the follow -up visit/end of trial visit, at t he time 
points specified in the flowchart  See overall  
Rationale  
 
Protocol version 4.0 (21 Jan 2021)  
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of  
Directive 2001/20/EC of the European Parliament and the Council of the European Union1. 
 
Overall rationale for preparing protocol, version 4.0:  
The overall rationale for  the changes implemented in the amended protocol is to account for 
collection of vital status and to include additional blood sampling for PK assessment following 
comments received from the Food and Drug Administration (FDA), US. Plasma semaglutide 
concent rations will be used to describe the exposure -response analysis. In addition, information 
regarding the COVID -[ADDRESS_1109033] been made.  
 
Section # and name  [CONTACT_18054] 1.2 Flowchart   Correction of minor errors  
 Addition of “Semaglutide 
plasma concentration” row  
 Removal of “Barrier and 
motivation interview” row  
 Footnotes updates  For clarification and to 
account for inclusion of 
PK samples  
Section 2 Introduction  Correction of references  For clarification  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 80 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  81 of 88 
 
Section # and name  [CONTACT_18054] 6.1.1  Medical Devices  Removal of the sentence, “Subjects 
will have access to training pen -
injectors for cushion injection at the 
clinical site prior to treatment 
dosing.”  For clarification  
Section 6.5 Concomitant 
medication   Addition of COVID -[ADDRESS_1109034] of medication  
 Addition of text regarding 
weight management d rugs For inclusion of 
COVID -19 vaccine and 
for clarification 
regarding weight 
management drugs  
Section 7.1 Discontinuation of trial 
treatment  Removal of text, “A treatment 
discontinuation session must be 
made in IWRS.”  For clarification  
Section 7.1.1  Temporary 
discontinuation of trial treatment   Removal of text, “In such cases 
a treatment discontinuation 
session should not be made in 
the IWRS.”  
 Replacement of text, “however 
treatment discontinuation 
session should not be made in 
IWRS”  
 Replacement of text “If acute 
pancreatitis is confirmed, 
treatment with trial product 
should not be restarted, and a 
treatment disc ontinuation 
session should be made in 
IWRS.”  For clarification  
Section 7.[ADDRESS_1109035] 
discontinuation/withdrawal from 
the trial   Replacement of text, “ If acute 
pancreatitis is confirmed, 
treatment with trial product 
should not be restarted, and a 
treatment discontinuation 
session should be made in 
IWRS .” 
 Addition of text regarding vital 
status  For clarification and to 
account for collection of 
vital stat us 
Section 7.[ADDRESS_1109036] to follow -up Addition of text  To account for 
collection of vital status  
Section 8 Trial assessments and 
procedures  Removal of bullet point regarding 
barriers and motivation interview  For clarification  
Section 8.3 Adverse events and 
serious adverse events  Addition of text  To include information 
regarding COVID -19 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 81 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  82 of 88 
 
Section # and name  [CONTACT_18054] 8.5 Pharmacokinetics  Addition of section  To account for inclusion 
of PK samples  
Section [IP_ADDRESS]  Pharmacokinetic 
and/or pharmacodynamic 
modelling  Addition of section  To account for inclusion 
of PK samples  
Section 10.1.12  Responsibilities  Addition of text  To align with changes in 
the protocol template  
Section 10.2 Appendix 2, Table 
10-1  Addition of text describing 
disclosure of results  
 Addition of PK sampling to 
efficacy laboratory assessments  For clarification 
regarding the blinding 
plan, and to comply 
with additions to 
Sections 8.5 and [IP_ADDRESS]  
Section 10.[ADDRESS_1109037]  
Section 10.9 Appendix 9  Addition of COVID -19 and PK  For clarification  
 
Protocol version  3.0 (07 January 2021)  
This amendment is considered to be non -substantial based on the criteria set forth in Article 10(a) of  
Directive 2001/20/EC of the European Parliament and the Council of the European Union1 because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
 
Overall rationale for preparing protocol, version 3:  
The overall rationale for the change implemented in the amended protocol is to address comments  
received from the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).  
 
Section # and 
name  [CONTACT_803330]  10.7: 
Appendix [ADDRESS_1109038] is mandatory for female 
subjects of childbearing potential  See overall  
rationale  
 
Protocol version 2.0 (05 January 2 021) 
This amendment is considered to be non -substantial based on the criteria set forth in Article 10(a) of  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 82 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  83 of 88 
 
Directive 2001/20/EC of the European Parliament and the Council of the European Union1 because 
it neither significantly impacts the safety nor physical/mental integrity of subjects nor the scientific 
value of the trial.  
 
Overall rationale for preparing protocol, version 2:  
The overall rationale for the changes implemented in the amended protocol is to address comments  
received from the Medicines & Healthcare products Regulatory Agency (MHRA).  
 
Section # and 
name  [CONTACT_18054]  10.7: 
Appendix [ADDRESS_1109039] is mandatory for female 
subjects of childbearing poten tial See overall  
rationale  
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 83 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  84 of 88 
 
11 References  
1. The European Parliament and the Council of the European Council. Directive 2001/20/EC 
of the European Parliament and of the Council of [ADDRESS_1109040] Obese Phenotype of Heart Failure With Preserved Ejection Fraction. 
Circulation. 2017;136(1):6 -19. 
3. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Disc overy of the once -
weekly glucagon -like peptide -1 (GLP -1) analogue semaglutide. J Med Chem. 
2015;58(18):7370 -80. 
4. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon -like 
peptide -1 promotes satiety and reduces food intake in pa tients with diabetes mellitus type 2. 
Am J Physiol. 1999;276(5 Pt 2):R1541 -4. 
5. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and 
safety of once -weekly semaglutide monotherapy versus placebo in patients with type 2 
diabetes (SUSTAIN 1): a double -blind, randomised, placebo -controlled, parallel -group, 
multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251 -60. 
6. Aroda VR, Bain SC, Cariou B, Pi[INVESTIGATOR_17972]č M, Rose L, Axelsen M, et al. Efficacy and  safety of 
once -weekly semaglutide versus once -daily insulin glargine as add -on to metformin (with or 
without sulfonylureas) in insulin -naive patients with type 2 diabetes (SUSTAIN 4): a 
randomised, open -label, parallel -group, multicentre, multinational, p hase 3a trial. Lancet 
Diabetes Endocrinol. 2017;5(5):355 -66. 
7. Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and 
safety of once -weekly semaglutide versus once -daily sitagliptin as an add -on to metformin, 
thiazolidinedio nes, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56 -week, 
double -blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341 -54. 
8. Ahmann A, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and 
safety of once -weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 
diabetes (SUSTAIN 3).  European Association for the Study of Diabetes, 52nd meeting 
2016, Oral Presentation #1472016.  
9. Rodbard H, Lingvay I, Reed J, de la Rosa R, Rose L, S ugimoto D, et al. Efficacy and safety 
of semaglutide once -weekly vs placebo as add -on to basal insulin alone  or in combination 
with metformin in subjects with type 2 diabetes (SUSTAIN 5) [abstract]. Diabetologia. 
2016;59(Suppl 1):[ADDRESS_1109041] T, et al. Effects of once -
weekly semaglutide on appetite, energy intake, control of eating, food preference and body 
weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242 -51. 
11. O'Neil PM, Bir kenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. 
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in 
patients with obesity: a randomised, double -blind, placebo and active controlled, dose -
ranging, ph ase 2 trial. Lancet. 2018;392([ZIP_CODE]):637 -49. 
12. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: 
pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711 -25.e6.  
13. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co -
morbidities related to obesity and overweight: a systematic review and meta -analysis. BMC 
Public Health. 2009;9:88.  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 84 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  85 of 88 
 
14. Pi[INVESTIGATOR_17968] T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, et al. Gene ral 
and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105 -20. 
15. Berghofer A, Pi[INVESTIGATOR_17968] T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity 
prevalence from a European perspective: a systematic review. BMC Public Health. 
2008;8:200.  
16. Masters RK, Reither EN, Powers DA, Yang YC, Burger AE, Link BG. The impact of 
obesity on US mortality levels: the importance of age and cohort factors in population 
estimates. Am J Public Health. 2013;103(10):1895 -901. 
17. Arnold M, Pandeya  N, By[CONTACT_18050] G, Renehan AG, Stevens GA, Ezzati M, et al. Global burden 
of cancer attributable to high body -mass index in 2012: a population -based study. Lancet 
Oncol. 2015;16(1):36 -46. 
18. World Health Organization. Obesity: Preventing and Managing the Globa l Epi[INVESTIGATOR_901]. Report 
of a WHO Consultation. World Health Organisation Geneva, Switzerland. 2000.  
19. Thomsen M, Nordestgaard BG. Myocardial Infarction and Ischemic Heart Disease in 
Overweight and Obesity With and Without Metabolic Syndrome. JAMA internal med icine. 
2013;174(1):15 -22. 
20. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, Schwartz MW, et al. Obesity 
and type 2 diabetes: what can be unified and what needs to be individualized? Journal of 
clinical endocrinology and metabolism. 2011;96(6):16 54-63. 
21. Khaodhiar L, Cummings S, Apovian CM. Treating diabetes and prediabetes by [CONTACT_18051]. Curr Diab Rep. 2009;9(5):348 -54. 
22. Wheaton AG, Perry GS, Chapman DP, Croft JB. Sleep disordered breathing and depression 
among U.S. adults: National Health and Nutrition Examination Survey, 2005 -2008. Sleep. 
2012;35(4):461 -7. 
23. Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, 
Emberson J, et al. Body -mass index and cause -specific mortality in 900 000 adults: 
collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):[ADDRESS_1109042] A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden 
associated with overweight and obesity. JAMA. 1999;282(16):[ADDRESS_1109043] circumference to nonalcoholic fatty 
liver disease. Gastroenterology. 2006;130(7):2023 -30. 
26. Blagojevic M, Jinks C, Jeffery A, Jo rdan KP. Risk factors for onset of osteoarthritis of the 
knee in older adults: a systematic review and meta -analysis. Osteoarthritis Cartilage. 
2010;18(1):24 -33. 
27. Aroda V, Bain S, Cariou B, Pi[INVESTIGATOR_803293] M, Rose L, Axelsen MB, et al. Efficacy and safety of 
once-weekly semaglutide vs once -daily insulin glargine in insulin -naïve subjects with type 2 
diabetes (SUSTAIN 4). Endocrine practice. 2016.  
28. Lu TT, Secher A JJ, Alanentalo T, Juel Paulsen S, Hecksher -Sørensen J, Larsen JN, 
Baquero A, Knudsen LB. Semaglut ide interacts with hypothalamic neurons and lowers body 
weight in mice.  Poster discussion 1072 -P. American Diabetes Association, 77th Scientific 
Sessions, San Diego, CA, [LOCATION_003].9 –13 June 2017.  
29. Novo Nordisk A/S. Investigator's Brochure, semaglutide s.c. f or weight management and 
non-alcoholic steatohepatitis, projects NN9536 and NN9931 (edition 5). 2019.  
30. Oh A, Okazaki R, Sam F, Valero -Muñoz M. Heart Failure With Preserved Ejection Fraction 
and Adipose Tissue: A Story of Two Tales. Front Cardiovasc Med.  2019;6:110.  
31. Reddy YNV, Lewis GD, Shah SJ, Obokata M, Abou -Ezzedine OF, Fudim M, et al. 
Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: 
A RELAX Trial Ancillary Study. Mayo Clin Proc. 2019;94(7):1199 -209. 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 85 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  86 of 88 
 
32. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with 
preserved ejection fraction: from mechanisms to therapi[INVESTIGATOR_014]. Eur Heart J. 2018;39(30):2780 -
92. 
33. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task 
Force for the diagnosis and treatment of acute and chronic heart failure of the European 
Society of Cardiology (ESC)Developed with the special contribution of the H eart Failure 
Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129 -200. 
34. Suthahar N, Meijers WC, Ho JE, Gansevoort RT, Voors AA, van der Meer P, et al. Sex -
specific associations of obesity and N -terminal pro -B-type natriuretic peptide levels in th e 
general population. Eur J Heart Fail. 2018;20(8):1205 -14. 
35. Oktay AA, Rich JD, Shah SJ. The emerging epi[INVESTIGATOR_803294]. Curr Heart Fail Rep. 2013;10(4):401 -10. 
36. Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR, et al. Temporal Trends in the 
Incidence of  and Mortality Associated With Heart  Failure With Preserved and Reduced 
Ejection Fraction. JACC Heart Fail. 2018;6(8):678 -85. 
37. Dunlay SM, Roger VL, Redfield MM. Epi[INVESTIGATOR_803295]. Nat Rev Cardiol. 2017;14(10):591 -602. 
38. Paulus WJ. Unfolding Discoveries in Heart Failure. N Engl J Med. 2020;382(7):679 -82. 
39. The American Society for Metabolic and Bariatric Surgery, The Obesity Society, The 
American Society o f Bariatric Physicians and the American Association of Clinical 
Endocrinologists. Obesity is a Disease: Leading Obesity Groups Agree (Joint Press 
Release). 19 June 2013.  
40. Garner RE, Feeny DH, Thompson A, Bernier J, McFarland BH, Huguet N, et al. 
Bodywei ght, gender, and quality of life: a population -based longitudinal study. Qual Life 
Res. 2012;21(5):[ADDRESS_1109044] of self -reported long -term conditions - cross -sectional 
study from the south Yorkshire cohort dataset. BMC Public Health. 2013;13:1009.  
42. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass index 
and adverse cardiovascular outcomes in heart failure p atients with preserved ejection 
fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I -
PRESERVE) trial. Circ Heart Fail. 2011;4(3):324 -31. 
43. Nimptsch K, Konigorski S, Pi[INVESTIGATOR_17968] T. Diagnosis of obesity and use of obesity biomarkers 
in science and clinical medicine. Metabolism. 2019;92:[ADDRESS_1109045] of 
Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality 
of Life  in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A 
Randomized Clinical Trial. JAMA. 2016;315(1):36 -46. 
45. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. 
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J 
Clin Endocrinol Metab. 2015;100(2):342 -62. 
46. Dombrowski SU, Knittle K, Avenell A, Araujo -Soares V, Sniehotta FF. Long term 
maintenance of weight loss with non -surgical interventions in obese adults: system atic 
review and meta -analyses of randomised controlled trials. BMJ. 2014;348:g2646.  
47. Ferguson C, David S, Divine L, Kahan S, Gallagher C, Gooding M, et al. Obesity Drug 
Outcome Measures. A Consensus Report of Considerations Regarding Pharmacologic 
Inter vention [Internet]. 2012 [cited 2018 8 Aug].  
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 86 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  [ADDRESS_1109046] E, Yumuk V, Maislos M, Oppert JM, et al. Obesity: the 
gateway to ill health - an EASO position statement on a rising public health, clinical and 
scientific challenge in Europe.  Obes Facts. 2013;6(2):117 -20. 
49. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical 
Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract. 
2012;18(5):642 -8. 
50. Pasman WJ, Saris WH, Westerterp -Plantenga MS. Predictors of weight maintenance. Obes 
Res. 1999;7(1):43 -50. 
51. Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a 
systematic review. Obes Rev. 2010;11(7):[ADDRESS_1109047] LA, Delbr idge E, Purcell K, Shulkes A, Kriketos A, et al. Long -
term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):[ADDRESS_1109048] JC, Frühbeck G. 2014 EASO 
position statement on the us e of anti -obesity drugs. Obes Facts. 2015;8(3):166 -74. 
54. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC 
guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task 
Force for the Diagnos is and Treatment of Acute and Chronic Heart Failure 2012 of the 
European Society of Cardiology. Developed in collaboration with the Heart Failure 
Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803 -69. 
55. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification 
of acute pancreatitis -2012: revision of the Atlanta classification and definitions by 
[CONTACT_5757]. Gut. 2013;62(1):[ADDRESS_1109049] MW, Heidenreich PA, Krumholz HM,  Jones P, et al. 
Monitoring clinical changes in patients with heart failure: a comparison of methods. Am 
Heart J. 2005;150(4):707 -15. 
57. Burman CF, Sonesson C, Guilbaud O. A recycling framework for the construction of 
Bonferroni -based multiple tests. Stat Med. 2009;28(5):739 -61. 
58. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise 
training on health status in patients with chronic heart failure: HF -ACTION randomized 
controlled trial. JAMA. 2009;301(14):1451 -9. 
59. Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, et al. Dapagliflozin 
Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure 
With Reduced Ejection Fraction: The DEFINE -HF Trial. Circulation. 2019;140(18):1463 -
76. 
60. McEvoy BW. Missing data in clinical trials for weight management. J Biopharm Stat. 
2016;26(1):30 -6. 
61. Wang D, Pocock S. A win ratio approach to comparing continuous non -normal outcomes in 
clinical trials. Pharm Stat. 2016;15(3):[ADDRESS_1109050] amended by [CONTACT_941] 64th WMA General Assembly, 
Fortaleza, Brazil. October 2013.  
63. ICH Harmonised Tripartite Guideline. Guideline for Good  Clinical Practice E6(R2),  Step 4 
version. 09 Nov 2016.  
64. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial 
registration: a statement from the International Committee of Medical Journal Editors. N 
Engl J Med. 2004;351( 12):[ADDRESS_1109051] of 2007 as amended by [CONTACT_43679] "Clinical 
Trials Registration and Results Information Submission". 21 September 201 6. 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 87 88
CONFIDENTIAL
Protocol  
CONFIDENTIAL  Date:  09 September 2022  Novo Nordisk  
Trial ID: EX9536 -4665  Version:  6.0 
      Status:  Final  
      Page:  88 of 88 
 
66. The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down 
Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency, article 57. 30 
April 2004.  
67. The European Parliament and the Council of the European Council. Regulation (EC) No 
1901/2006 of the European Parliament and of the Council of 12 Dece mber 2006 on 
medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, article 41. 
Official Journal of the European Communities. [ADDRESS_1109052], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals; current version 
available at www.icmje.org.  
 
EX9536-4665 EX9536 0  | VV-TMF-5539529  . -  | 1
 |  of   Protocol  4665 V6 88 88
CONFIDENTIAL
9.1.1 Protocol Attachment
Protocol A ttachment I islocated in the Trial Master File .
If applicable , Protocol A ttachment II is also located in the Trial Master File.
Content: Global key staff and Country  key staff.CONFIDENTIALDate: Novo Nordisk
Version:
Status:Semaglutide s.c. 2.4 mg once weekly
Study ID: EX9536-4665
Clinical Study Report
Appendix 9.1.121 June 2023
1.0
Final
CONFIDENTIAL